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Even after an extensive etiological investigation in about one third of ischemic strokes it is not 
possible to establish a cause. A fraction of these strokes could have been due to an episode of 
paroxysmal atrial fibrillation which could not be identified. Studies show that the current 
available methods to diagnose paroxysmal atrial fibrillation have a low sensitivity. N-terminal 
of the brain natriuretic peptide (NT-proBNP) could be useful as a biomarker of cardioembolic 
stroke.  
NT-proBNP serum levels were initially evaluated in 66 ischemic atroke patients. Patients with 
cardioembolic stroke had higher levels of NT-proBNP than patients with non-cardioembolic 
stroke. NT-proBNP had a very good accuracy to diagnose cardioembolic stroke related to atrial 
fibrillation (AUC-0.92) Two cut-off points of serum NT-proBNP levels with a high sensitivity 
(265.5 pg/mL) and specificity (912 pg/mL) for the diagnosis of paroxysmal atrial fibrillation 
were established. Although NT-proBNP levels started to decrease 72 hours after stroke onset, 
the diagnostic accuracy of NT-proBNP to diagnose cardioembolic stroke was similar in the first 
72 hours after ischemic stroke. In a validation study performed in 184 patients the cut-off points 
of 265.5 pg / mL and 912.0 pg / mL of NT-proBNP had a sensitivity, specificity, positive 
predictive value and negative predictive value in the first study versus validation study of 
respectively (94.4% vs 100%, 72.9% vs 70.5%, 56.6% vs 59.1%, 97.2% vs 100%) versus 
(55.5% vs 81.8%, 97.9% vs 87.5, 90.9% vs 73.8%, 83.9 vs 91.9%) for the diagnosis of ischemic 
stroke of cardioembolic etiology associated to atrial fibrillation. A prospective study including 
80 patients was done to evaluate the cut-off points in patients with cryptogenic stroke. The Area 
Under the Curve of the Receiver Operating Curve of NT-proBNP for the diagnosis of 
paroxysmal atrial fibrillation  in patients with cryptogenic stroke was good - 0.83, 95% CI 
(0.73-0.92), the cut-off point of 265.5 pg/mL had a sensitivity of 88.2% 95% CI (65.7-96.7%). 
The cut-off point of 912 pg/mL had a specificity of 88.9% 95% CI (78.8-94.5%).  
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NT-proBNP may be useful as a biomarker for paroxysmal atrial fibrillation in ischemic stroke 



























Mesmo após uma extensa investigação etiologica, em aproximadamente um terço dos acidentes 
vasculares cerebrais (AVC) isquemicos não é possibel estabelecer uma causa. Uma fracção 
destes AVCs pode ter sido causada por episodios de fibrilhação auricular paroxistica que não 
foram identificado. Os estudos mostram que os métodos actuais de diagnostico de fibrilhação 
auricular paroxistica têm uma baixa sensibilidade. O N-terminal do peptideo natriuretico 
cerebral  (NT-proBNP) pode ser util como biomarcador de AVC cardioembolico.  
Os valores séricos de NT-proBNP forem inicialmente determinados em 66 doentes com AVC 
isquémico. Os doentes com  um AVC de etiologica cardioembolica tinham valores de NT-
proBNP superiores aos de doentes com uma etiologia não-cardioembolica. O NT-proBNP teve 
uma boa precisão para diagnosticar AVC cardioembolico relacionado com fibrilhação auricular 
(AUC-0.92). Dois pontos de corte de valores séricos de NT-proBNP com uma elevada 
sensibilidade  (265.5 pg/mL) e especificidade  (912 pg/mL) para o diagnostico de fibrilhação 
auricular paroxitica foram estabelecidos. Apesar de os valores séricos de NT-proBNP 
começarem a diminuir 72 horas após o inicio do acidente vascular cerebral, a precisão 
diagnostica do NT-proBNP para o diagnostico de AVC cardioembolico foi semelhante nas 
primeiras 72 horas após inicio do AVC. Num estudo de validação realizado em 184 doentes, os 
pontos de corte de 265.5 pg / mL e  912.0 pg / mL de NT-proBNP tiveram uma sensibilidade, 
especificidade, valor preditivo positive e valor preditivo no primeiro estudo versus estudo de 
validação de respectivamente  (94.4% vs 100%, 72.9% vs 70.5%, 56.6% vs 59.1%, 97.2% vs 
100%) versus (55.5% vs 81.8%, 97.9% vs 87.5, 90.9% vs 73.8%, 83.9 vs 91.9%) para o 
diagnostico de AVC isquémico de etiologia cardioembolic associado a fibrilhação auricular.   
Um estudo prospectivo que incluiu 80 doentes foi realizado para avaliar os pontos de corte em 
doentes com AVC criptogénico.  
A área sob a curva ROC da precisão diagnostica dos valores séricos de NT-proBNP para o 
diagnostico de fibrilhação auricular paroxistica nos doentes com AVC criptogenico foi boa -  - 
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0.83, 95% IC (0.73-0.92). O ponto de corte de 265.5 pg/mL teve uma sensibilidade de  88.2% 
95% IC (65.7-96.7%). O ponto de corte de 912 pg/mL teve uma especificidade de  88.9% 95% 
IC (78.8-94.5%).  
O NT-proBNP pode ser util como um biomarcador de fibrilhação auricular paroxística nos 
doentes com AVC isquémico. Poderá também ajudar a reclassificar AVCs inicialmente 









































































Stroke is a leading cause of disability and mortality. It is the third cause of death worldwide, the 
first cause of acquired disability, the second cause of dementia and is associated to significant 
direct and indirect costs [1]. In Portugal, it has an estimated incidence of 187 per 100000 
inhabitants and it is the first cause of death and dependency in patients older than 65 years. A 
cross-sectional study of a representative sample of the Portuguese population including subjects 
aged 40 reported a prevalence of atrial fibrillation of 2.5% (2.2-2.8%: 95% CI) [2].  With 
growing ageing of the world population and increasing incidence of vascular risk factors, the 
prevalence of stroke-related burden is expected to increase over the next two decades. Although 
there has been in the last decade an increased use of treatment during ischemic acute stroke, 
such as thrombolysis (intravenous or intraarterial) and implementation of stroke unit care, these 
are poorly effective and are available to only a small portion of the population. Resources 
should be potentiated to improve primary and secondary prevention of stroke. The majority of 
strokes worldwide (87%) are ischemic.  After the diagnosis of stroke, a thorough investigation 
should be undertaken in order to identify a specific etiology. The identification of a specific 
etiology has important clinical implications in terms of prognosis, recurrence risk and influences 
the short term management and the prescription of secondary prevention interventions.  
Ischemic stroke is often classified regarding etiology into cardioembolic, large vessel, small 
vessel, rare causes and cryptogenic causes. It is estimate from large studies that the cause of 
ischemic stroke is cardioembolic in 17-46% of cases [3].  
A cardioembolic etiology is attributable when the embolus that causes the occlusion of a 
cerebral vessel has a cardiac origin or when there is the passage of embolic material from the 
venous system through the heart (paradoxical embolism).  
Currently the most used ischemic stroke etiology classification is the “Trial of Org 10172 in 
Acute Stroke Treatment” (TOAST) criteria that first appeared in 1993 [4]. Using this 
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classification, in order to be classified as having a cardioembolic stroke etiology, patients have 
to have an arterial occlusions presumably due to an embolus arising in the heart. Cardiac 
sources are divided into high-risk and medium-risk groups based on the evidence of their 
relative propensities for embolism. At least one cardiac source for an embolus must be 
identified for a possible or probable diagnosis of cardioembolic stroke. Evidence of a previous 
transient ischemic attack or stroke in more than one vascular territory or systemic embolism 
supports a clinical diagnosis of cardiogenic stroke.  
In the A-S-C-O (Phenotypic) classification [5], which was defined in 2009, patients are 
evaluated for 4 predefined phenotypes, atherosclerosis (A), small vessel disease (S), cardiac 
disease (C) and other causes (O). The first step is to ‘grade’ every patient in each of the 4 main 
ischemic groups. Three grades of likelihood are considered:  
• Grade 1: definitely a potential cause of the index stroke; 
• Grade 2: causality uncertain; 
• Grade 3: unlikely a direct cause of the index stroke (but disease is present). 
Three levels are added for the diagnostic instruments used: 
• Level A: direct demonstration by gold-standard diagnostic tests or criteria; 
• Level B: indirect evidence or less sensitive or specific tests or criteria; 
• Level C: weak evidence in the absence of specific tests or criteria. 
 
The cardiac pathologies that may cause brain embolism may be systematized in seven main 
groups [6]: 
a) Arrhythmias, especially atrial fibrillation (AF), atrial flutter and sick sinus disease; 
b) Valve heart diseases including mitral stenosis, prosthetic heart valves, infectious 
endocarditis and marantic endocarditis; 
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c) Changes in ventricular myocardium leading to ventricular dilatation, these may can be 
caused by cardiomyopathies, ischemic heart disease or myocarditis; 
d) Intracardiac masses, such as thrombus or tumoral masses, namely atrial myxomas; 
e) Intracardiac shunts, specially “patent foramen ovale” and interatrial septal defects, 
leading to a paradoxical embolism mechanism; 
f) Atrial lesions such as left atria enlargement; 
g) Aortic lesions, namely aortic atherosclerotic plaques; 
 
The most frequent cardiac source of embolism is the left atrium and the left appendage.  
The most common underlying disorder responsible for cardioembolism in ischemic stroke in 
developed countries is non-valvular atrial fibrillation [3,7].  
 
 
1.2 Atrial fibrillation  
 
Atrial fibrillation is a supraventricular arrhythmia characterized by an unorganized activation of 
the electrical atrial activity leading to an inefficient atrial contraction [8].  
There are two mechanisms that have been proposed to underlie the initiation and perpetuation of 
atrial fibrillation: first, rapid ectopic activity may trigger and maintain atrial fibrillation. Second, 
sustained atrial fibrillation may depend on single or multiple electrical re-entrant circuits 
resulting from shortening of effective refractory periods and from localized deceleration of 
intra-atrial conduction. In addition to initiation by electrical trigger beats, re-entry requires a 
susceptible substrate such as fibrosis. Both mechanisms are not mutually exclusive [9]. There 
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are also genetic mutations as well as several loci associated with atrial fibrillation that suggest 
increased individual susceptibility to this arrhythmia [10]. These were identified through 
analysis of rare monogenetic hereditary atrial fibrillation conditions or using genome-wide 
association studies. The resulting decrease in atrial contraction leads to blood stasis and to an 
increased probability of thrombus formation. In locations with stasis, a low laminar blood flux 
and other factors activate the classical coagulation cascade, leading to thrombus formation. In 
patients with atrial fibrillation without valve disease, stasis takes place mainly in the atrial 
appendages. More than 90% of thrombi detected in transesophageal echocardiograms in patients 
with non-valvular atrial fibrillation were located in the left atrium [11]. It has also been 
suggested that in patients with atrial fibrillation there is an increase in platelet activation and in 
thrombin activation that may contribute to a hypercoagulability state [12]. Various 
inflammatory markers (C-reactive protein, tumor necrosis factor-α, interleukin-2, interleukin-6, 
and interleukin-8) have been associated to atrial fibrillation. Proposed mechanisms linking 
inflammation and the prothrombotic atrial fibrillation state include endothelial 
activation/damage, production of tissue factor from monocytes, increased platelet activation, 
and increased expression of fibrinogen [13].  
Atrial fibrillation has a prevalence of 0.4 to 1% in the population of developed countries in 
general. The prevalence of atrial fibrillation increases with age, and is higher in men than in 
women [7,14].  The percentage of strokes attributable to atrial fibrillation increases from 1.5% 
at 50 to 59 years of age to 23.5% at 80 to 89 years of age [15]. About 70% of patients with atrial 
fibrillation have an age comprised between 65 and 85 years old [16]. Atrial fibrillation is an 
established risk factor for ischemic stroke and therefore one of the most important findings in 
the context of the cardiac investigation of patients with ischemic stroke.  
Patients with atrial fibrillation have an associated five-fold increased risk of stroke than patients 
without this arrhythmia [17].  Stroke related to atrial fibrillation is generally severe with an 
estimated mortality of 50% in the first year after stroke, has a high recurrence rate and results in 
significant costs, mobility and mortality [8]. No strategy to pursue a normal sinus rhythm after 
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atrial fibrillation, including cardioversion, antiarrhythmic drugs or ablation, has been shown to 
reduce the risk of stroke.  In the study ATHENA (A Placebo-Controlled, Double-Blind, Parallel 
Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of 
Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial 
Fibrillation/Atrial Flutter), the maintenance of a sinus rhythm following atrial fibrillation by 
Dronedarone resulted in a decrease in hospitalization by cardiovascular causes in which stroke 
or transient ischemic attack (TIA) were included [18].  
Regarding its temporal pattern, atrial fibrillation can be classified as paroxysmal, persistent or 
permanent. It is classified as paroxysmal whenever it terminates spontaneously or by an induced 
mechanism in less than seven days after its onset. Paroxysmal atrial fibrillation may present as a 
brief single episode of arrhythmia or as clusters of abnormal rhythm of variable duration. It 
usually lasts less than 48 hours. Whenever atrial fibrillation lasts more than seven days but is 
ended by a spontaneous or induced way it is classified as persistent. Whenever atrial fibrillation 
is maintained, regardless of attempted cardioversion or not, it is designated as permanent [8]. 
Paroxysmal atrial fibrillation comprises between 25% to 62% of atrial fibrillation cases. The 
natural history is for paroxysmal episodes to increase until they become persistent. Paroxysmal 
atrial fibrillation has the same risk as persistent or permanent atrial fibrillation to cause an 
ischemic stroke [19]. It was generally considered that only episodes of paroxysmal atrial 
fibrillation with more than 30 seconds of duration were  of prognostic importance. However, a 
recent study showed that even high atrial rates of short duration comprising a few seconds are 
associated with higher risk for acute and chronic brain infarcts [20,21]. 
Previously, the main cause of atrial fibrillation was rheumatic fever. Currently, due to a 
decrease in the incidence of rheumatic fever, atrial fibrillation is mainly related to ischemic 
heart disease, hypertensive heart disease, congestive heart failure and diabetes mellitus. When 
atrial fibrillation is related to one of these causes it is designated as non-rheumatic or non-
valvular atrial fibrillation [8].  
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Although it is frequently related to structural heart disease, about 45% of patients with 
paroxysmal atrial fibrillation and 25% with persistent atrial fibrillation have no 
echocardiographic detectable heart disease [8]. In elderly patients the development of atrial 
fibrillation is mostly related to cardiac disorders, whereas younger patients may develop atrial 
fibrillation in the absence of underlying heart disease (“lone AF”) [9]. Lone AF usually 
becomes manifest earlier in life and may have a stronger genetic predisposition than common 
atrial fibrillation [22].   
There are echocardiograph changes that indicate a particular high risk of embolism in patients 
with atrial fibrillation such as: increased left atria size, decreased flux velocities in the left atrial 
appendage, mitral valve annulus calcification and left ventricular dysfunction [23]. About 13% 
of patients with non-rheumatic atrial fibrillation have detectable thrombus in a transesophageal 
echocardiogram [24]. It is unknown if these patients have a definitely higher risk of ischemic 
stroke than patients with no detectable thrombus [25].  
Some clinical classification schemes have been proposed for predicting stroke in patients with 
non-valvular atrial fibrillation, one of the most frequently used in clinical practice is the 
CHADS2 score (Congestive Heart Failure, Hypertension, Age, Diabetes Mellitus and Stroke). 
This score was proposed in 2006 assigns 1 point for the presence of each of the included risk 
factors for stroke except for a history of stroke or transient ischemic attack that is assigned with 
a 2 points score. Patients with a CHADS2 score of 0 or 1 have a 1% annual risk of stroke. 
CHADS2 scores of 2 have a an annual risk of stroke of 2.5% and patients with a score equal or 
higher than 3 have an annual risk of stroke of more than 5%. [26].  Since 2006, stronger 
evidence has accumulated that additional risk factors should be considered in assessing 
thromboembolic risk and would be of value in identifying those patients at truly low risk.  
The additional risk factors have been expressed in the CHA2DS2-VASc (Congestive heart 
failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischemic 
attack, Vascular disease, Age 65-74 years, Sex category. In this score, age≥75 years and 
previous stroke carry doubled risk weight [27]. The diagnosis of a cardioembolic etiology 
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related to atrial fibrillation is particularly important for secondary stroke prevention. Although 
the majority of patients after an ischemic stroke receive antiplatelets as a secondary prevention 
treatment, including patients with a stroke of undetermined etiology, in the case of ischemic 
stroke related to atrial fibrillation, Vitamin-K antagonists are clearly superior to aspirin in the 
secondary prevention of stroke as shown in the European Atrial Fibrillation (EAFT) trial [28, 
29]. The new anticoagulant drugs such as Rivaroxaban [30], Dabigatran [31] or Apixaban [32, 
33] also reduce the risk of ischemic stroke in patients with atrial fibrillation. Currently, oral 
anticoagulation with vitamin K antagonists (INR 2.0-3.0) after ischemic stroke in patients with 
atrial fibrillation is recommend by the European Stroke Organization (ESO) with an evidence 
level of Class I, Level A [34].   
As ischemic stroke in patents with atrial fibrillation is associated with greater disability and 
mortality than in those without atrial fibrillation, establishing the presence of underlying atrial 
fibrillation is of clinical importance. 
 
1.3 Atrial fibrillation diagnosis 
 
The gold standard for the diagnosis of atrial fibrillation is the visual inspection of the 
electrocardiogram. Guidelines from the European Society of Cardiology (ESC) define atrial 
fibrillation as a cardiac arrhythmia with the following characteristics: the surface ECG shows 
absolutely irregular RR intervals; there are no distinct P waves on the surface ECG; and the 
atrial cycle length (ie, the interval between two atrial activations), when visible, is usually 
variable and less than 200 ms (>300 beats per min) [35]. Due to the importance of the diagnosis 
of atrial fibrillation in the context of ischemic stroke all patients should do at least one 12 lead 
ECG in the etiological workup of stroke, as recommended by both the American Heart 
Association and the European Stroke Organization [34, 36]. The diagnosis of persistent or 
permanent atrial fibrillation is straightforward. However, the diagnosis of paroxysmal atrial 
fibrillation can be quite challenging as it is often asymptomatic and can be present for only a 
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few fractions of seconds making it frequently clinically underdetected. In one study, less than 
one-third (32%) of the palpitation symptoms corresponded to atrial fibrillation, with a greater 
percentage (39%) being in sinus rhythm [37]. This difficulty in diagnosis paroxysmal atrial 
fibrillation prevents an early detection and timely beginning of therapeutics [38]. In patients 
with an undetermined stroke etiology and when a cardioembolic stroke etiology is suspected, it 
is also recommended to do a 24 hours ECG recording (Holter) [34, 36]. 
To date, several studies have explored the use of prolonged noninvasive and invasive cardiac 
monitoring devices to identify atrial fibrillation. However, studies show that the current 
available methods to detect paroxysmal atrial fibrillation have a low sensitivity. It remains 
elusive which is the best method and the duration of monitoring to detect paroxysmal atrial 
fibrillation. It is known that a 24 hours ECG recording has a higher sensitivity for the diagnosis 
of paroxysmal atrial fibrillation than a routine 12 lead ECG. In a systematic review [39] the 
detection rate of paroxysmal atrial fibrillation by a 24-72 hours ECG recording was of 4.6%. 
Due to the low detection rate of this examination, there is some controversy regarding its 
clinical utility and its routine use in the etiological investigation of ischemic stroke [40].  Serial 
ECG assessments within the first 72 hours of an acute stroke significantly improve detection of 
atrial fibrillation [41]. Automated analysis of continuous stroke unit ECG monitoring improves 
paroxysmal atrial fibrillation detection in patients with stroke on stroke units compared with 24-
hour Holter ECG [42].  
Longer recordings such as with a 7-day ambulatory ECG monitoring using an event-loop 
recording (ELR) device  detected paroxysmal atrial fibrillation in more 6 to 8% of patients after 
a non-diagnostic 24 hours ECG monitoring  [43]. The use of 7 days event-loop recorders at 0, 3 
and 6 months after stroke onset detected paroxysmal atrial fibrillation in 14% of patients with an 
initial negative 24 hours ECG monitoring   [39]. Nevertheless in order to register events using 
this device it is necessary to have the patient collaboration. The patient activates the registry of 
events after feeling palpitations. Periods of asymptomatic atrial fibrillation are therefore not 
registered. A Mobile Cardiac Outpatient Telemetry during a period of 21 days in patients with 
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cryptogenic transient ischemic attack or stroke resulted in a paroxysmal atrial fibrillation 
detection rate of 23% [44]. One study suggested that in patients with acute ischemic stroke, 
frequent atrial premature beats (> or = 70/24 hours) could be a marker for individuals who are at 
higher risk to develop or have paroxysmal atrial fibrillation. For such patients, it was proposed a 
diagnostic workup with repeated prolonged ECG monitoring to diagnose paroxysmal atrial 
fibrillation [45]. However the use of long term monitoring was reported to have compliance 
problems to be cumbersome by both patients and nursing staff [46].  
An implantable loop recorder study found paroxysmal atrial fibrillation is 25% of patients with 
an initial cryptogenic stroke [47]. However, a major limitation of this method is the need of a 
surgical procedure required for the device implantation.  
Table 1 summarizes the main methods of cardiac monitoring.  
 
Methods of cardiac monitoring  pAF detection rate 
Non-invasive  
Continuous hospital telemetry 
Ambulatory ECG (Holter) 
 
Patient-triggered event recorder 
 





Invasive   
Implantable loop recorder 
 
Pacemakers and defibrillators 
25% 





There is currently undergoing a clinical trial “Cryptogenic Stroke and underlying Atrial 
Fibrillation” (CRYSTAL AF), whose goal is to evaluate the incidence of atrial fibrillation and 
time to atrial fibrillation detection in patients with cryptogenic stroke using an insertable cardiac 
monitor during a 1-year period [48]. 
Currently there is no evidence of prognostic utility in ischemic stroke of electrophysiological 
studies that measure the atrial refractory period and the times of conduction to define an index 
of atrial vulnerability to fibrillation (latent atrial vulnerability). In the epidemiological study 
“Ischemic stroke and atrial vulnerability” (ISAV), the presence of atrial vulnerability in patients 
with cryptogenic ischemic stroke did not correlate with the occurrence of events such as 
recurrent stroke or atrial arrhythmia [49]. 
As patients with paroxysmal atrial fibrillation have a high risk of recurrent stroke and 
anticoagulation is significantly superior to antiplatelets for the secondary prevention of 
cardioembolic stroke, alternative ways to detect a possible cardioembolic etiology in 
cryptogenic stroke must be considered. 
Currently, about one third of ischemic strokes are classified as of undetermined etiology. It is 
possible that a fraction of these strokes named as cryptogenic may be due to an undetected 
episode of atrial fibrillation [50, 51]. 
The importance of a correct identification of stroke etiology leads me to posit that biomarkers 
studied acutely in patients with brain ischemia could identify some cardioembolic sources of 
embolism. 
 
1.4  Biomarkers 
 
The first reference to the term biomarker appeared in PubMed in 1977 [52]. It was first defined 
in 1989 in the Medical Subject Heading (MeSH) as a “ Measurable and quantifiable biological 
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parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene 
phenotype distribution in a population, presence of biological substances) which serve as 
indices for health and physiology related assessments, such as disease risk, psychiatric 
disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, 
substance abuse, pregnancy, cell line development, epidemiologic studies, etc.” [53]. In 2008, 
the definition was reviewed and biomarker became defined as “a molecular, biological, or 
physical characteristic that indicates a specific physiologic state. It is used in clinical practice to 
identify risk for disease, diagnose disease and its severity, guide intervention strategies, and 
monitor patient responses to therapy” [54].    
Biomarkers have been progressively recognized as important diagnostic tools. Ideally, a 
biomarker should be highly sensitive, specific, accessible, accurate, reproducible by an 
analytical method, cost-effective and have a result that can be easily interpreted by a physician 
[55].  
Examples of blood biomarkers used in clinical practice include cardiac troponins in myocardial 
infarction, human choriogonadotropin to diagnose pregnancy, and creatinine that is used to 
monitor renal function. 
In the context of stroke, biomarkers have been studied for [56]: 
- Diagnosis of ischemic stroke; 
- Diagnosis of ischemic stroke versus hemorrhagic stroke; 
- Identification of ischemic stroke phases (as markers of definitive ischemic lesion or of 
potentially recoverable tissue corresponding to penumbra); 
- Determination of stroke etiology; 
- Determination of clinical prognosis;  
- Response to treatment 
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Biomarkers under investigation in stroke are or specific to the central nervous system or 
markers of systemic inflammation, fibrinolysis or hemostasis. Possible biomarkers from the 
blood, cerebrospinal fluid and brain tissue have been investigated [57]. Preferably a blood or 
serum derived biomarker should be used, as it is more accessible, less invasive and could be 
monitored in time through serial measurements.  
There are two great obstacles to the use of biomarkers in cerebrovascular pathology: 
a) The presence of the blood-brain barrier that difficult and delays the release of proteins 
of neuronal or glial origin into the bloodstream after stroke;  
b) Many of the potential serum biomarkers of cerebral ischemia and inflammation have a 
low specificity and may also be increased in situations that can be confounded with 
stroke in their presentation such as acute myocardial infarction or central nervous 
system inflammation [58] 
Presently around 58 possible stroke related biomarkers have been studied. Four of these proteins 
have been studied as possible blood based biomarkers of cardioembolic stroke. There are also 
studies investigating if there are gene expressions signatures in blood that could be suggestive 
of cardioembolic stroke [59,60]. Using whole-genome microarrays, a 40-gene profile that 
distinguished cardioembolic stroke from large-vessel stroke, and a separate 37-gene profile 
that distinguished cardioembolic stroke due to atrial fibrillation from nonatrial fibrillation 
causes was identified. These genes play roles in inflammation [59].  Nevertheless none of these 
biomarkers can be recommend to be used in clinical practice.   
 
Table 2 displays the characteristics of the main serum biomarkers that have been evaluated in 
the context of ischemic stroke related to atrial fibrillation.  








Peptide with heart and brain 
production  




Product of fibrin degradation  ↑acute, subacute and chronic phases 




Glycoprotein involved in 
hemostasis 




Integral membrane protein 
expressed on the surface of 
endothelial cells, serves as a 
cofactor for thrombin 
↑ acute ischemic stroke (atrial 
fibrillation)  
 
Table 2 – Resume of the characteristics of the main serum biomarkers that have been 
studied in the context of ischemic stroke related to atrial fibrillation, ↑ - increased  
 
One of the substances that have been studied as a possible biomarker of cardioembolic stroke is 




1.5 Brain natriuretic peptide and N-terminal proBrain natriuretic peptide 
 
 
NT-pro BNP is part of a group of natriuretic peptides, phylogenetically conserved along time 
that includes peptides such as atrial natriuretic peptide (ANP), natriuretic peptide type C, 
urodilatin and the Dendroaspis natriuretic peptide [65].  
NT-proBNP is coded by a gene composed by three exons and two introns that is located in 
chromosome 1p36.2. It is initially produced as a prepropeptide of 143 amino acids. This 
prepropeptide is proteolytic cleaved into a non-active N-terminal fragment composed by 108 
amino acids designated proBNP. ProBNP after secretion is divided in two fractions by two 
proteolytic enzymes. These two fractions are BNP that is biological active (aa 77-108) and the 
N-terminal-proBNP (NT-proBNP) (aa 1-76) without biological activity [66].  BNP and NT-
proBNP concentrations can be determined in blood samples [67]. The half-life of these two 
peptides differs. NT-proBNP has a half-life superior to BNP.  NT-proBNP has a half-life of 120 
minutes and BNP a half-life of 22 minutes [68]. It is due to this difference in half-life that most 
essays measure NT-proBNP instead of BNP.  
Although NT-proBNP was initially isolated in porcine brain in 1988 [69], explaining its 
designation as brain natriuretic peptide, subsequent experiences showed that it also had a 
cardiac production [70]. Currently it is considered that the heart is its main production site.  In 
the brain, NT-proBNP is mainly produced in the hypothalamus. The cerebral cortex, thalamus, 
pons have also been pointed as possible production sites [71]. NT-proBNP in normal conditions 
does not cross the bold-brain barrier [72]. 
In the heart, BNP can be produced by both atria and ventricles [72]. After being produced NT-
proBNP and BNP are mainly secret in “bursts”. Their storage in granules is minimal [73].  
Concerning tissue expression, BNP seems to be more present in the atria rather than in the 
ventricles. However, due to the larger ventricular mass, 70% of all BNP is produced by the 
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ventricle in normal conditions [74].  The observation of ventricular BNP gene expression in 
ventricular disease may have contributed to the common notion that BNP is mainly a ventricular 
hormone.  
The main stimulus for the synthesis and excretion of BNP is myocites stretching, mainly in the 
context of volume [75] or cardiac pressure overload [76]. After myocites stretching there is a 
rapid activation, within hours, of NT-ptoBNP gene expression [77]. Heart fibroblasts can also 
produce NT-proBNP. Heart hypertrophy, fibrosis and hypoxia can also stimulate NT-proBNP 
production [78].  Certain hormones (catecholamines, angiotensin II and endothelin-1) may 
stimulate the production of NT-proBNP through paracrine or endocrine mechanisms [79]. 
Biological actions of BNP are mediated by the receptor of the natriuretic peptides of type A 
(NPR-A). This receptor is a guanylyl cyclase receptor. It is a transmembrane receptor with 120 
kD. It is composed by an extracellular region that connects to BNP and an intracellular kinase 
and guanylyl cyclase domain with enzymatic activity. This receptor is mainly located in the 
cellular membrane of the endothelium of small vessels [80].  BNP connection to the receptor 
leads to the conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate 
(cGMP) [81]. A kinase protein dependent on cGMP (PKG or cGK) is the principal intracellular 
mediator of cGMP signals through a catalytic transference of the phosphate of present in TPA to 
a serine or threonine residue present in the target protein [82]. Signal transduction activated by 
these receptors is terminated by a GMP phosphodiesterase that modulates the intracellular 
concentration of cGMP and the duration and magnitude of the response [83].  
BNP acts by an endocrine mechanism. It has an important role in the cardiovascular 
homeostatic regulation and in volume control. BNP biological effects include natriuresis, 
diuresis, vasodilatation, inhibition of the renin-angiotensin-aldosterone axis and of the 
sympathetic nervous system [84]. In the heart BNP has a lusitropic and antifibrotic effect [85].  
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Know mechanisms of BNP inactivation include connection to the type C receptor of clearance 
of the natriuretic peptides and proteolysis by the peptidase NEP 24.1. NT-proBNP is cleared 
from circulation through the kidney by direct filtration and passive excretion [86].  
In healthy individuals, BNP and NT-proBNP plasmatic concentrations are similar. They can be 
detected in venous blood samples in picomolar concentrations. However, in congestive heart 
failure patients, NT-proBNP concentration is two to ten times higher than BNP concentration. 
The explanation for this difference is unknown. Serum NT-proBNP and BNP levels in healthy 
individuals increase with age and are higher in women than in men [87].  The reason for this 
age-related increase in BNP or NT-proBNP is presumed to be related to the parallel age increase 
in subclinical structural heart disease, including heart muscle disease, diastolic abnormalities, 
valve disease and arrhythmia [88]. An age-related decrease in renal function is also considered 
to be partially responsible. Ninety percent of young adults have NT-proBNP levels below 70 
pg/mL [89]. NT-proBNP plasmatic levels correlate with left ventricular mass.  A NT-proBNP 
cut-off superior to 300 pg/mL has been suggested for the diagnosis of congestive heart failure 
[90]. NT-proBNP is currently used as a marker of left ventricular dysfunction and of prognosis 
in patients with congestive heart failure and in acute ischemic heart disease [91]. High NT-
proBNP levels have been registered in patients with renal failure, anaemia, acute pulmonary 
embolism, pulmonary hypertension, sepsis, hyperthyroidism, mitral and aortic regurgitation and 
dysrhythmias such as atrial fibrillation [92, 93].  
Patient with lone paroxysmal atrial fibrillation seem to have increased NT-proBNP levels when 
compared to patients in sinus rhythm, in the absence of a structural heart disease [94]. Increased 
plasmatic levels of NT-proBNP have been found in patients with permanent or paroxysmal 
atrial fibrillation with preserved left ventricular systolic function [95]. One study showed that in 
81% of patients NT-proBNP levels increased within four hours of the onset of atrial fibrillation 
[96]. It has also been documented, after electric cardioversion of atrial fibrillation to sinus 
rhythm, a return to baseline of NT-proBNP values [97]. NT-proBNP has been shown to be a 
remarkable predictor of incident atrial fibrillation in the general population, independently of 
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any other previously described risk factor [98]. Recent studies that suggest that NT-proBNP is a 
predictor of atrial fibrillation following cardiac surgery [99-101] and successful cardioversion 
[102].  
 
There is currently no established explanation for the increase of BNP in the context of atrial 
fibrillation. In the isolated atria tissue of rat, alpha1-adrenergic stimulation with phenylephrine 
induces genetic expression of BNP [103]. It is unknown if alpha1-adrenergic stimulation results 
in an increase in the synthesis of BNP in patients with atrial fibrillation. A study that analysed 
human right atrial tissue found that persistent atrial fibrillation was associated to a high 
expression of proBNP mRNA. However, patients with paroxysmal atrial fibrillation did not 
have changes in proBNP gene expression [104].  
 
1.6  NT-proBNP and BNP  in ischemic stroke  
 
Although NT-proBNP presence was first described in the brain tissue, information regarding 
NT-proBNP in ischemic stroke is small.  
Some studies showed an acute increase in NT-proBNP and BNP serum levels in acute ischemic 
stroke (Table 3).  These studies initially aimed to determine if NT-proBNP or BNP could be 
used as prognostic markers of acute ischemic stroke along with other markers of myocardial 
injury such like troponins. It was suggested that it could be used as a marker of long term bad 
prognosis. It was then noticed that patients with acute ischemic stroke tended to have higher 
levels of NT-proBNP and BNP when taking in account the cut-off points used for the diagnosis 
of congestive heart failure.  
Four possible explanations for the increase of NT-proBNP and BNP during acute ischemic 
stroke where proposed in these studies: 
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- Patients with acute ischemic stroke frequently have several vascular risk factors and may have 
an associated acute or chronic heart failure. Therefore, the increase in NT-proBNP levels could 
be due to ventricular dysfunction; 
- The increase in NT-proBNP levels could be due to atrial fibrillation. Atrial fibrillation is a 
major risk factor for ischemic stroke and a known cause of NT-proBNP increase; 
- As the brain is a site of BNP and NT-proBNP production, although it only produces a small 
amount of these peptides it is possible that after an acute ischemic lesion there is a release of 
BNP and NT-proBNP that is measurable in the plasma.   
- BNP has an inhibitory action in the central and peripheral sympathetic nervous system. BNP 
could be increased in acute ischemic stroke as a response to the increase sympathetic activity 
that occurs after stroke  
- Autonomic changes of acute ischemic stroke are frequently associated to right insular cortical 
ischemia [105]. Insular cortical ischemia has been associated to an increase in the serum levels 
of norepinephrine, electrocardiographic changes and changes in the circadian patterns of blood 
pressure.   In these cases, there is an inflammatory response with increase of interleukin 6. 
Interleukin 6 can directly increase BNP and NT-proBNP levels.  
 





174 Increase of NT-proBNP levels in acute ischemic stroke, when 
using as cut-off points the levels used for the diagnosis of 
congestive heart failure 
Increase of NT-proBNP levels could be due to ventricular 
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dysfunction or be due to sympathetic nervous system activation 
Makikallio, 
2005 [107] 
51 Increase of NT-proBNP levels in acute ischemic stroke when 
comparing with healthy controls. 
Increase of NT-proBNP could have a brain origin  
Nakagawa, 
2005 [108] 
88 Increase of NT-proBNP in the acute phase of ischemic stroke, 
decrease in the subacute phase 
NT-proBNP levels correlated with mean blood pressure 
Giannakoulas, 
2005 [109] 
30 Higher increase of NT-proBNP in cardioembolic stroke than in 
large vessels diseases related ischemic stroke 




250 NT-proBNP levels in the second day after ischemic stroke 
associated to 6 months mortality 
Itumur 2006 
[111] 
57 Patients with ischemic stroke with insular cortical involvement 
and with signs of myocardial ischemia had higher levels of NT-
proBNP than other patients with ischemic stroke. However this 
increase was not statically significant  
Yip 2006 
[112] 
86 Ischemic stroke patients with higher NT-proBNP levels had a 
higher number of unfavorable clinical events (acute myocardial 
infarction, congestive heart failure, recurrent stroke or any other 
cause of death) 
Koenig 2007 72 The increase of NT-proBNP in acute ischemic stroke was not 
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707 Several potential biomarkers were studied.  
Levels of BNP> 76 pg/mL in patients with acute ischemic stroke 
indicated a cardioembolic etiology with a sensitivity of 72%, a 
specificity of 69% and a negative predictive value of 82%.  
Naya 2008 
[115] 
76 NT-proBNP levels and the evaluation of flow in the left atria 
appendage could help to distinguish cardioembolic stroke related 
to atrial fibrillation from other etiologies 
Gartner 2008 
[116] 
222 A statistically significant association was found between the 
plasmatic concentration of BNP and the severity of clinically 
silent brain infarctions related to atrial fibrillation  
Tomita 2008 
[117] 
79 Plasmatic levels of BNP were statistically significantly higher in   
patients with acute ischemic stroke with a large vessels etiology. 
Patients with a cardioembolic etiology were excluded from the 
study. BNP levels were positively correlated with the NIH stroke 
scale classification and with the volume of the ischemic lesion  
Shibazaki K, 
2009 [118] 
200 Plasma BNP level is significantly higher in cardioembolic  
patients than in other stroke subtypes, and thus physicians 
should strongly consider cardioembolism when the plasma BNP 
level is over 140.0 pg/mL in patients with acute ischemic stroke 
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Saritas A 2010 
[119] 
123 
Patients who had atrial fibrillation in their electrocardiography 
had significantly higher BNP levels than patients in sinus 
rhythm. A positive correlation was found between plasma BNP 
levels with age, blood urea nitrogen and NIHSS and a negative 
correlation was found between plasma BNP levels and GCS. 






High plasma BNP level should be a strong predictor of delayed 




The combination of AF and BNP>150pg/ml was a useful 
predictor for no early recanalization after IV-t-PA therapy 
Okada  2011 
[122] 
67 
In patients with AF in acute ischemic stroke or TIA , a BNP 
concentration of>140.0 pg/ml (odds ratio, 5.62; 95% CI, 1.39-






Plasma BNP level of > 320 pg/ml (OR, 4.74; 95% CI, 1.260-









In a previous study [124], we analyzed whether NT-proBNP was elevated in patients with acute 
ischemic stroke of cardiac cause. We used a sample of consecutive acute stroke patients with 
ischemic or intracerebral hemorrhage that were admitted from November 2007 to August 2008 
to the Stroke Unit of Hospital de Santa Maria, Lisbon, Portugal. 
Patients with a history of conditions known to increase NT-proBNP (acute ischemic heart 
disease, heart failure, heart valve disease, renal failure, cardiomyopathies, pulmonary 
hypertension, anemia) were excluded. Patients with subarachnoid hemorrhage, cerebral venous 
thrombosis and transient ischemic attack were also not included in this study. 
After patient admission from the emergency department, information on demography, vascular 
risk factors, or previous atrial fibrillation was collected. A brain CT scan, done after hospital 
admission, was used to classify strokes as hemorrhagic or ischemic. It was repeated 48–72 h 
after hospital admission to outline the ischemic area. When the ischemic area was not evident in 
a CT scan, a 1.5 T magnetic resonance imaging (MRI; including diffusion-weighted imaging) 
was performed. All patients had transcranial Doppler and carotid and vertebral duplex scanning. 
Etiological workup included, in all patients with ischemic stroke, complete blood count, 
erythrocyte sedimentation rate, hepatic and renal function, glucose and lipid levels, protein 
electrophoresis and coagulation studies. In patients less than 55 years old, workup included 
autoantibodies, lupus anticoagulant, anticardiolipin antibodies, C and S protein, antitrombin III, 
fibrinogen levels, HIV 1 and 2, Hepatitis B and C serologies. Transthoracic echocardiogram 
was performed in all patients. Patients with echocardiographic evidence of heart disease 
(shortening fraction less than 30%, valve dysfunction, cardiomyopathies, akinetic ventricular 
wall regions) were excluded. 
The following parameters were registered: 
- left atria autocontrast 
- intracardiac thrombus 
- shortening fraction 
- patent foramen oval (PFO), and 
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- akinetic ventricular wall regions. 
In patients less than 55 years old a transesophageal echocardiogram was also performed. To 
determine the presence of atrial fibrillation at least two ECGs were done during hospital stay, 
and when the stroke cause remained undetermined a 24 h Holter monitoring was also 
performed. In patients whose stroke cause remained undetermined, lumbar puncture or cerebral 
angiography was done. Patients with hemorrhagic stroke had blood analysis, ECG and a 
transthoracic echocardiogram. Ischemic stroke causes were classified according to TOAST [4] 
classifications in five groups; large-artery atherosclerosis, cardioembolic, small-vessel 
occlusion, stroke of other determined cause and stroke of undetermined cause. For the present 
study, patients were subdivided in two groups; cardioembolic cause (corresponding to the 
cardioembolic classification of TOAST) and noncardioembolic cause (all other four groups of 
the TOAST classification). Ischemic stroke topography was dichotomized in anterior/carotid 
territory or posterior/vertebrobasilar territory, accordingly to CT or MRI information. Infarct 
size was classified according to the ASPECTS scale [125], using CT-scan or MRI information. 
To evaluate autonomic nervous system activation three measurements of systolic blood pressure 
(SBP), diastolic blood pressure (DBP) and heart rate (HR) were done at eight-hour intervals 
after patient admission. In the first 72 h after symptoms onset, four milliliters of blood was 
drawn from a peripheral vein. Blood samples were immediately centrifuged at 1600 g during 15 
min. Serum concentration of NT-proBNP was determined by an electrochemiluminescence 
assay using the Elecsys 2010 immunoassay analyzer [126]. 
A descriptive statistical analysis of demographic and vascular risk factors of patients with 
ischemic stroke, hemorrhagic stroke, cardioembolic and noncardioembolic cause was 
performed. Data distribution was evaluated using histograms and a one-sample Kolmogorov–
Smirnov test. For comparison between groups the w2-test, Fisher exact test, Mann–Whitney test 
or t-test were used as appropriate. As NT-proBNP values did not follow a normal distribution, a 
logarithm transformation was done. To compare NT-proBNP values between different timings 
of blood collection, a one-way analysis of variance was used. t-test was used to compare mean 
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values of NT-proBNP between patients with intracerebral hemorrhage versus ischemic stroke , 
cardioembolic stroke versus noncardioembolic stroke and cardioembolic stroke related to atrial 
fibrillation versus noncardioembolic stroke. Receiver operating characteristic (ROC) curves 
were used to test the ability of NT-proBNP to identify cardioembolic stroke and cardioembolic 
stroke associated with atrial fibrillation. The area under the curve (AUC) for each ROC curve 
was determined. Based on the ROC curves, NT-proBNP values with the highest sensitivity and 
specificity for the diagnosis of cardioembolic stroke and cardioembolic stroke related to atrial 
fibrillation were determined as well as the corresponding positive and negative predictive values 
(NPV). 
To study the association between NT-proBNP and systolic blood pressure, diastolic blood 
pressure and heart rate, a simple linear regression was calculated. The corresponding regression 
coefficients with 95% confidence intervals (CI) were determined. To evaluate differences in 
NT-proBNP values between arterial territories,   t-student test was used. To evaluate the 
association between ischemic area and NT-proBNP value a Kendall correlation analysis was 
performed.  
From November 2007 to August 2008, 202 stroke patients were admitted to the Stroke Unit. 
Ninety-two patients were included. The main reasons for exclusion were: heart diseases known 
to increase NT-proBNP (32.7%), subarachnoid hemorrhage (29.1%) and patient admission 72 h 
after stroke onset (18.2%). Included patients had a mean age of 58.6  (SD +/- 14.4) years. 
Women were 64.1% of the patients. Sixty-six (71.7%) patients had an ischemic stroke and 26 




 Ischemic stroke (n=66) Hemorrhagic stroke (n=26)        p 
Gender, female (%) 26 (39.4) 7(26.9) 0.26 
Age, years (mean, SD) 60.6(14.9) 53.6(11.9) 0.035 
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Vascular risk factors 
   Hypertension (%) 
   Diabetes mellitus (%) 
   Dyslipidemia (%) 
   Smoking (%) 



















   SBP, mmHg (mean, SD) 
   DBP,mmHg (mean, SD)  














Table 4 – Demographic data, vascular risk factors and vital parameters of patients with ischemic 
and hemorrhagic stroke, SBP – Systolic blood pressure, DBP – diastolic blood pressure, HR - 
heart rate, SD – standard deviation, AF – atrial fibrillation 
 
According to the TOAST classification 28 patients had a cardioembolic cause and 38 were 
noncardioembolic: 12 (18.2%) large arteries; seven (10.6%) small vessels; five (7.6%) other 
determined; 14 (21.2%) undetermined. Cardioembolic cause included 18 patients with atrial 
fibrillation (12 paroxysmal, six permanent) and 10 patients with patent foramen ovale. 
Demographic data, vascular risk factors and vital parameters of patients with cardioembolic 
ischemic stroke and noncardioembolic ischemic stroke were not significantly different (Table 
2). The two subgroups of patients with cardioembolic and noncardioembolic cause were not 
significantly different concerning arterial territory or insular involvement or infarct size 
evaluated by the ASPECTS scale (Table 5).  
 
 Cardioembolic stroke (n=28) Noncardioembolic stroke (n=38)    p 
Gender, male (%) 15 (53.6) 25 (65.8) 0.32 
Age, years (mean, SD) 63 (16) 59 (14) 0.24 
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Vascular risk factors 
   Hypertension (%) 
   Diabetes mellitus (%) 
   Dyslipidemia (%) 
















Anterior territory (%) 












   SBP, mmHg (mean, SD) 
   DBP,mmHg (mean, SD)  














Table 5 – Demographic data, vascular risk factors, stroke characteristics and vital parameters of 
patients with cardioembolic and noncardioembolic stroke, SBP – Systolic blood pressure, DBP 
– diastolic blood pressure, HR - heart rate, SD – standard deviation 
 
No intracardiac thrombus or left atria autocontrast were detected during echocardiography. The 
NT-proBNP values followed a positively skewed distribution and ranged from 8 to 6378 pg/ml 
with a median of 177.0 pg/ml. After a logarithm transformation, a new variable was obtained, 
which followed a normal distribution. In 21 patients (22.8%), blood was collected in the first 24 
h, in 62 patients (67.4%) in the first 24–48 h and in nine patients (9.8%) in the first 48–72 h. 
The mean value (95% CI) of NT-proBNP in patients with ischemic stroke was 223.18 (157.42–
316.40) pg/ml and in patients with hemorrhagic stroke was 133.34 (74.13–239.82) pg/ml. 
However, this difference was not statistically significant (P=0.12). The mean of NT-proBNP 
values in patients with ischemic stroke in the carotid artery territory was 275.88 (95% CI 
179.47–419.89) pg/ml and in patients with stroke in the vertebrobasilar territory was 138.83 
(74.44– 259.82) pg/ml. This difference was not statistically significant (P=0.10). No statistically 
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significant association was found between infarct size evaluated by ASPECTS scale and serum 
values of NT-proBNP (P=0.11). No significant linear relationship was found between NT-
proBNP values and systolic blood pressure (P=0.091) or diastolic blood pressure (P=0.26). A 
significant linear relationship was found between NT-proBNP values and heart rate with a 
regression coefficient of 0.025 pg/ml/bpm, (P= 0.039). The mean of NT-proBNP values for 
cardioembolic stroke was significantly higher (P<0.001) (491.6; 95% CI 283.7–852.0 pg/ml) 




Figure 1- Serum concentration of NT-proBNP in patients with noncardioembolic and 
cardioembolic ischemic stroke. Boxplots present median values and interquartile ranges 
 
The ROC curve of NT-proBNP values for the diagnosis of cardioembolic stroke had an AUC 
(95% CI) of 0.77 (0.65–0.89). The cut-off point with the highest sensitivity and specificity was 
set at 265.5 pg/ml (71.4% and 73.7% respectively). This point had a NPV of 77.8%and a 
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positive predictive value (PPV) of 66.6% (Figure 2). The AUC of NT-proBNP obtained for the 
diagnosis of cardioembolic stroke related to AF was 0.92 (0.86–0.99). This AUC value was 
higher than the value obtained for the diagnosis of cardioembolic stroke in general (0.92 versus. 
0.77). After analysis of the ROC curve for the diagnosis of cardioembolic stroke related to atrial 
fibrillation a cut-off point of 265.50 pg/ml was determined (sensitivity of 94.4%, specificity of 
72.9%, positive predictive value of 56.6% and a negative predictive value of 97.2%). This cut-
off point had an extremely high negative predictive value. However, in the context of clinical 
decisions, it is more important to confirm the diagnosis of cardioembolism as it leads to a 
change in clinical decision; therefore another cut-off point with a higher positive predictive 
value was determined. The cut-off point of  912.0 pg/ml had a sensitivity of 55.5%, specificity 




Figure 2 –ROC curves illustrating the accuracy of NT-proBNP to identify cardioembolic stroke 
(A) and cardioembolic stroke associated to atrial fibrillation (B) 
 
This study suggests that the increase of NT-proBNP which occurs during stroke has a cardiac 
origin and may be due to atrial fibrillation. The mean value of NT-proBNP in patients with 
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cardioembolic ischemic stroke was significantly higher than in patients with noncardioembolic 
ischemic stroke. No significant association was found between stroke territory or infarct size 
and NT-proBNP values, or between systolic blood pressure or diastolic blood pressure and NT-
proBNP values. The ROC curve for the diagnosis of cardioembolic stroke had an AUC of 0.77 
which corresponds to a good ability of NT-BNP to diagnose cardioembolic stroke. The ROC 
curve for the diagnosis of cardioembolic stroke associated to atrial fibrillation had an AUC of 
0.92 which suggests that NT-proBNP has a very good ability to diagnose ischemic stroke 
associated to atrial fibrillation, being useful to differentiate it from other etiologies. Although 
previous studies had suggested a cardiac cause they had not excluded the presence of 
confounding variables, which could have caused the increase of NT-proBNP. Namely Montaner 
[61] and Shibazaki [118] did not exclude the presence of renal failure, heart failure and ischemic 
heart disease. In our study, to decrease possible confounding factors, patients with known 
causes of NT-proBNP increase, such as renal failure and heart failure, ischemic heart disease 
and valvular heart disease, were excluded, using both clinical and echocardiographic evidence. 
Also, Montaner [61] and Shibazaki [118] did not analyze if this increase could be due to the 
large infarct area that patients with cardioembolic stroke tend to have [127]. In their patients, the 
increase of NT-proBNP could have been due to a large infarct area, as it is established that NT-
proBNP is also produced in the brain [69, 128]. In our study, we analyzed this variable and we 
did not find an association between stroke territory or infarct size and NT-proBNP values. One 
recent study [122] suggested that the increase of NT-proBNP in stroke could be due to atrial 
fibrillation. However, the authors did not exclude patients with heart failure and found that the 
variable ‘congestive heart failure’ was significantly higher in the atrial fibrillation group than in 
non-atrial fibrillation group. Therefore the increase of the NT-proBNP could not be securely 
attributed to atrial fibrillation, because heart failure is a cause of NT-proBNP increase [91]. In 
our study, levels of NT-proBNP were compared between hemorrhagic and ischemic stroke 
based in the hypothesis that if the increase of NT-proBNP was purely due to a ischemic stroke 
cause subtype – cardioembolic – and not to other factors such as autonomic activation, there 
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would be higher levels of NT-proBNP in patients with ischemic stroke than in hemorrhagic 
stroke. In fact, patients with ischemic stroke had higher levels of NT-proBNP (223.18 (157.42–
316.40) pg/ml) than patients with hemorrhagic stroke (33.34 (74.13–239.82) pg/ml). However, 
this difference was not statistically significant (P=0.12) probably due to the modest number of 
patients included. When comparing only patients with ischemic stroke, after excluding possible 
confounding variables, we found that the mean value of NT-proBNP in patients with 
cardioembolic ischemic stroke was significantly higher than in patients with noncardioembolic 
ischemic stroke. Due to the exclusion criteria, the number of possible heart embolic sources was 
restricted to two: atrial fibrillation and patent foramen ovale. Patent foramen ovale can be a 
cardioembolic source due to paradoxical embolism or due to the induction of changes in the 
electrical activity of the left atria leading to atrial arrhythmias, such as paroxysmal atrial 
fibrillation or atrial flutter [129]. It may be therefore able to increase NT-proBNP values. After 
analysis of the ROC curve for ischemic stroke associated to atrial fibrillation, a cut-off point of 
265.5 pg/ml with a high sensitivity (94.4%) and a high negative predictive value (97,2%) was 
determined. The cut-off point of 912.0 pg/ml had a positive predictive value of 90.9%. If this 
cut-off point is confirmed in another sample it can lead to a high suspicion of atrial fibrillation 
in patients with stroke of undetermined cause. A NT-proBNP level above this cut-off may help 
to select patients for prolonged heart rhythm monitoring to detect paroxysmal atrial fibrillation. 
In the previously mentioned studies [61, 121, 122], blood was drawn in the first 24 h after 
stroke onset. In our study, blood was drawn in the first 72 h after stroke onset (although mostly 
in the first 24–48 h). The option for an enlarged inclusion time was based on the knowledge that 
a sizable proportion of patients does not go to the hospital in the first 24 h after stroke onset 
[130].  Available data is unclear regarding the timing when maximum serum concentration of 
NT-proBNP in ischemic stroke is achieved. Giannakoulas [109] did not find a statistically 
significant difference between day one and six after stroke onset. Jensen [110] noticed a peak in 
the second day, with a progressive decrease in NT-proBNP until day five. Iltumur [111] 
described highest values of NT-proBNP in the day of stroke onset. In our study no significant 
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difference was found between the different timings of drawing blood samples. One limitation of 
our study is the modest number of patients included; nevertheless it obtained some statistically 
significant results. Other limitations relate to the use, in the majority of patients, of CT instead 
of MRI to evaluate the infarct area and location. The study of possible biomarkers of ischemic 
stroke subtypes may be clinically valuable. Our results suggest that NT-proBNP can be a useful 
biomarker of certain causes of cardioembolic stroke, namely atrial fibrillation. Our results must 
be replicated in an independent sample. It is necessary to conduct another study on a different 
sample, with a larger number of patients to validate the cutoff points established. It is also 
necessary to identify possible sources of variation of NT-proBNP and in particular to establish 
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The increase of serum NT-proBNP levels in ischemic stroke may be used in the 
classification of the etiology of ischemic stroke as a marker of high risk cardioembolic 




















































1) Describe the temporal evolution of the values of NT-proBNP in the first 72 hours after onset 
of symptoms of ischemic stroke, making measurement of the NT-proBNP 24, 48 and 72 hours 
after onset of stroke symptoms.  
 
2) Validate the previously determined values of sensitivity and specificity for the cutoff points 
of 265.5 pg / mL and 912.0 pg / mL of NT-proBNP (94.4%, 72.9% and 55.5 %, 97.9%) for the 
diagnosis of ischemic stroke of cardioembolic etiology associated with atrial fibrillation.  
 
3) To analyze if the previous established cut-off values of NT-proBNP have a similar accuracy 
to diagnose cryptogenic stroke associated to paroxysmal atrial fibrillation.  
 
4) To analyze if individuals with stroke of undetermined etiology, with a clinical or imaging 
pattern suggestive of cardioembolism, at the hospital and in whom atrial fibrillation (ECG or 
Holter) is subsequently detected, have higher values of NT-proBNP at the index event than 

















































Part of this chapter was published in the following article:  
 
 Fonseca AC, Matias JS, E Melo TP, Pires C, Geraldes R, Canhão P, Brito D, Ferro JM. Time 
course of NT-proBNP levels after acute ischemic stroke. Acta Neurol Scand 2013;128:235-
240. 
 
And presented as an oral communication at the 20th European Stroke Conference, 2011 
 
 Fonseca AC, Sampaio Matias J, Pinho e Melo T, Pires C, Canhão P,  Geraldes R, 
J.M. Ferro. Time course of N-terminal pro-brain natriuretic peptide in acute ischemic 






























The identification of a specific ischemic stroke etiology has important clinical implications in 
terms of prognosis, recurrence risk and influences the short term management and the 
prescription of secondary prevention interventions.  
Particularly important is the identification of a cardioembolic etiology, namely atrial fibrillation 
(AF), as studies have shown that anticoagulation is superior to antiplatelet agents for the 
prevention of recurrent stroke [1]. Stroke related to AF tends to be severe, with a mortality rate 
at the first year of 50% and is associated to a high recurrence rate [2].  
Identifying paroxysmal AF can be particularly difficult as auxiliary complementary 
examinations can be entirely unremarkable. Literature shows that the current available methods 
(ECG, routine telemetry during inpatients admission, Holter monitoring, 30-day event 
monitoring devices) to detect paroxysmal AF have a low sensitivity [3]. Therefore it is plausible 
that cases of undetected paroxysmal AF may contribute to a large fraction of the approximately 
1/3 of strokes which are currently classified as of undetermined etiology [4].  
Serum biomarkers may be useful in this context. Recent studies suggest that NT-proBNP may 
be useful as a serum biomarker of cardioembolic stroke, namely associated with AF [5,6,7].  
NT-proBNP is produced by the atrial and ventricle myocytes in stressful conditions such as 
hemodynamic overload. Namely, following the hemodynamic effect of atrial fibrillation, 
granules stored in atrial myocites are secreted as BNP and NT-proBNP [8], leading to the high 
levels of NT-proBNP.  
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However, to use NT-proBNP as a biomarker of cardioembolic stroke it is necessary to know its 
short term kinetic after stroke in order to determine the best time to measure it. Currently, there 
is scarce and contradictory data about the best time to measure NT-proBNP after stroke [9,10].  
In this study, we aimed to characterise NT-proBNP serum levels in the first three days after 




Type of study 
Observational, cross-sectional study  
 
Study Population  
We studied a consecutive sample of patients with ischemic stroke according to the World Health 
Organization criteria [11] or transient ischemic attack (TIA) [12] that were admitted to the 
Stroke Unit of the Neurology Department of the Hospital de Santa Maria, Lisboa, from 
December 2009 to June 2010 and from October 2010 to December 2010. In order to be included 
the patients had to be admitted within 24 hours of stroke onset and have blood collections done 
at 24, 48 and 72 hours after stroke onset.  Patients were excluded if they had acute renal failure 
or chronic renal insufficiency (glomerular filtration rate glomerular determined by the equation 
of Cockcroft-Gault, less than 90 mL / min, hemodialysis or peritoneal dialysis).   
 
Clinical Protocol 
Patients with ischemic stroke were admitted from the Emergency Department and transferred to 
the Stroke Unit.  
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During hospital stay, information on demography, vascular risk factors, or previous atrial 
fibrillation was collected.  
Hypertension was defined as a personal history of systolic blood pressure superior to 140 
mmHg or/and diastolic blood pressure superior to 90 mmHg in two time periods before hospital 
admission or evidence of treatment with antihypertensive drugs.   
The patient was considered to have diabetes mellitus whenever there was a previous diagnosis 
of diabetes mellitus, treatment with oral antidiabetics or insulin or there was after hospital 
admission a fasting blood glucose >126 mg/dL or/and post-prandial blood glucose > 200 mg/dL 
and/or tolerance test with blood glucose levels >200 md/dL at the 2º hour) or A1C > 6.5%. 
Smoking was considered whenever there was a current or past history of smoking.  
The patient was considered to have dyslipidemia if there was a previous diagnosis of 
hypercholesterolemia or hypertriglyceridemia or treatment with lipid-lowering drugs  
The establishment of previous atrial fibrillation implied a personal history of atrial fibrillation or 
electrocardiographic evidence of this arrhythmia previous to the current hospital admission  
Ischemic heart disease was defined as a personal history of angor, myocardial infarction or 
coronary revascularization.  
Anemia was defined as hemoglobin levels below 12.0 g/dL.  
Treatment at the time of stroke onset with drugs that could eventually cause changes in NT-
proBNP serum levels such as angiotensin-converting enzyme inhibitors (ACEI), Angiotensin II 
receptor blockers (ARB), diuretics and Beta-blockers was also registered.  
 
NT-proBNP measurements   
In patients who complied with the study criteria, 4 ml of blood were drawn from a peripheral 
vein, at the first 24 (Day 1), 48 (Day 2) and 72 hours (Day 3) after stroke onset.  Whenever 
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stroke symptoms were first noticed on awakening the time of stroke onset was considered as the 
time when the patients had last been seen asymptomatic. Blood samples were immediately 
taken to the Clinical Pathology Department to measure serum levels of NT-proBNP. NT-
proBNP levels were measured by an electrochemiluminescence assay using the Elecsys 2010 
immunoassay analyzer (Roche Diagnostics, Mannheim, Germany) [13]. In this assay there is a 
simultaneous reaction between a polyclonal biotinylated NT-proBNP antibody and a ruthenium 
labeled polyclonal NT-proBNP antibody. These antibodies create a “sandwich” complex with 
the NT-proBNP that is present in the blood. The complex antigen-antibody is captured by a 
biotin-streptavidin reaction. The mixture that results from the reaction is aspired into a reading 
cell where the microparticles are magnetically captured to the surface of an electrode. The 
application of voltage to the electrode induces an emission that is measured. The software that is 
included in the system converts the intensity of the signal in a quantitative value.  
A cut-off of NT-proBNP of 300 pg/ml has been suggested for suspicion of congestive heart 
failure [14]. The assay has a coefficient of variation in the range of 1.0 to 6.0%. 
 
Stroke etiology determination  
Laboratorial etiological workup included in all patients determination of a complete blood 
count, erythrocyte sedimentation rate, hepatic function, glucose and lipid levels, creatinine, 
protein electrophoresis, prothrombin time and activated partial thromboplastin time. In patients 
less than 55 years old, laboratorial workup also included evaluation of autoantibodies, lupus 
anticoagulant, anticardiolipin antibodies, C and S protein, antithrombin III, fibrinogen levels, 
HIV 1 and 2, Hepatitis B and C serologies.  
Regarding neuroimaging, in all patients a brain-CT or Magnetic Resonance Imaging including 
diffusion-weighted imaging (MRI) (80.2%) was performed. 
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To study the intracranial and extracranial vessels all patients underwent transcranial Doppler 
and carotid and vertebral duplex scanning. Twenty eight patients (27,7%) had Magnetic 
Resonance Angiography. In 16 patients (15.8%) digital cerebral angiography was performed.  
All patients underwent transthoracic echocardiogram. This exam was done blinded to NT-
proBNP levels. The following parameters were registered: left atria dimensions, ejection 
fraction, presence of left atrial spontaneous echo contrast, intracardiac thrombus, patency of 
patent foramen oval (PFO), diastolic dysfunction [15] and hypokinetic/akinetic left ventricular 
segments. Systolic dysfunction was defined as a left ventricular ejection fraction <50%. In 
patients less than 55 years old a transesophageal echocardiogram was also performed. To 
diagnose atrial fibrillation, at least two ECGs and one 24-hours Holter monitoring were done 
during hospital stay.  
Stroke etiological classification was done using the TOAST criteria [16]. Stroke subtypes were 
further grouped in cardioembolic and non-cardioembolic.  The non-cardioembolic group 
included the subtypes of large-artery atherosclerosis, small vessels occlusion, stroke of other 
determined cause and stroke of undetermined cause.  
 
The study was approved by the Ethic Committee of Hospital de Santa Maria, Lisbon, Portugal. 




A descriptive statistical analysis of demographic and vascular risk factors of patients with 
ischemic stroke, cardioembolic and non-cardioembolic cause was performed. Data distribution 
was evaluated using histograms and a one sample Kolmogorov-Smirnov test. For normally 
distributed data, results were presented with mean and standard deviation (SD). For non-
normally distributed data, median and interquartile ranges were defined. For comparison 
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between groups the chi-square test, Fisher exact test, Mann-Whitney test or T-test were used as 
appropriate.   
To compare NT-proBNP values between the 3 different timings of blood collection, Friedman 
test was used. This was performed for all ischemic stroke patients and for those with 
cardioembolic and noncardioembolic stroke. Post-hoc analysis with Wilcoxon Signed-Rank 
Tests was conducted with a Bonferroni correction.  
Mann-Whitney test was used to compare the median values of N-BNP between groups of 
patients with cardioembolic stroke vs noncardioembolic stroke. 
Receiver Operating Curves and the Area Under the Curve to determine the accuracy of NT-
proBNP to diagnose cardioembolic stroke were determined at each time point.   





Between December 2009 – June 2010 and October 2010 – December 2010, 160 patients with 
ischemic stroke or TIA were admitted to the Stroke Unit. One hundred and one patients were 
included in the study (93 with stroke, 8 with TIA). Main reasons for patients’ exclusion from 
the study were: admission more than 24 hours after stroke onset (n=26), unavailability of 3 
measurements (n=14), less than 3 days of hospital stay (n=10), renal failure (n=1). 
Included patients had a mean age of  64.5 years with a standard deviation (SD) of 12.3. 
Minimum age was 31 years and the maximum age was 86. Table 1 shows the characteristics of 
included patients. Classification of stroke etiology according to TOAST criteria is presented in 
Table 1. The main stroke etiology was undetermined followed by cardioembolic etiology. Other 
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determined etiology was due to artery dissection in two cases and hypercoagulable conditions in 
four cases (immunoglobulins infusion 1, iron deficiency anemia 1, antiphospholipid syndrome 
1, and thrombocytosis 1). 
Table 1 - Characteristics of the included patients 
 
 All Cardioembolic Noncardioembolic p 
Patients (n) 101 29 72  
Age, years (mean +/- SD) 64.5 +/- 
12.3  
65.4 +/- 12.2 63.5 +/- 12.6 0.53 
Gender, Female (n,%) 42 (41.6) 16 (55.2) 25 (34.7) 0.06 
Hypertension (n,%) 71 (70.3) 19 (65.5) 52 (72.2) 0.51 
Diabetes mellitus (%) 25 (24.8) 6 (21) 19 (26.4) 0.55 
Dyslipidaemia (n,%) 33 (32.7) 8 (27.6) 25 (34.7) 0.49 
Anemia (n,%) 11 (10.9)  6 (20.7) 5 (6.9) 0.07 
ACEI or ARB (n,%) 50 (49.5) 13 (44.8) 37 (51.4) 0.55 
Beta-blockers (n,%) 25 (24.8) 9 (31.0) 16 (22.2) 0.35 
Diuretics (n,%) 31 (30.7) 8 (27.6) 23 (31.9) 0.67 
Systolic dysfunction (n,%) 6 (6.0) 4 (13.8) 2 (2.8) 0.06 
Diastolic dysfunction (n=76)  32 (42.1) 5 (23.8) 27 (49.1) 0.05 
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SD – standard deviation, ACEI – angiotensin converting enzyme inhibitors, ARB - angiotensin 
receptor blockers, Hypokinetic VS – Hypokinetic ventricular segment, Dil. Cardiomyop – 
Dilated cardiomyopathy, PFO – Patent Foramen Ovale, ASA – Atrial Septal Aneurysm 
 
Three hundred and three NT-proBNP determinations were done. The NT-proBNP serum 
determinations were done at exactly the following time points:  mean (SD) 23h02m (1h51m), 
46h50m (2h40m,) and 71h17m (2h42m). NT-proBNP values did not follow a normal 
distribution across the three time points (24, 48, 72 h). They had a positively skewed 
distribution. Median values of NT-proBNP were highest in the first 24 hours after ischemic 
stroke and decreased in the following time points The difference of NT-proBNP values across 
the 3 time points was statistically significant (p<0.001) (Figure 1). When we analyzed 
individual differences between the specific time points, there was no significant difference in 
NT-proBNP values at Day 1 versus Day 2 (p=0.34). Values of NT-proBNP were different at 
Day 2 versus Day 3 (p<0.001).   
 
Figure 1 - NT-proBNP levels in the first 24, 48 and 72 hours in all patients.  Boxplots present 




NT-proBNP values in patients with cardioembolic stroke (n=29) were higher than in patients 
with non-cardioembolic stroke (n=72) in the three time points (p<0.001); (Table 1).  
The same pattern of NT-proBNP values kinetic was observed in patients with cardioembolic 
and noncardioembolic stroke. NT-proBNP values were not significantly different in the first 2 
days. However, in the third day there was a statically significant decrease, Cardioembolic Day 1 
vs Day 2 vs Day 3 p=0.035, Day 1 vs Day 2 p=0.42, Day 2 vs Day 3 p=0.023, 
Noncardioembolic Day 1 vs Day 2 vs Day3 p<0.001, Day 1 vs Day 2 p=0.10, Day 2 vs Day 3 




Figure 2 – Serum levels of NT-proBNP in patients with cardioembolic (n=72) and 
noncardioembolic stroke (n=29) in day 1-3. NT-proBNP values expressed in pg/mL 
 
The Receiver Operating Curves of NT-proBNP at 24, 48 and 72 hours for the diagnosis of 
cardioembolic stroke had a similar very good Area Under the Curve (AUC) (Figure 3). The 
Areas Under the Curve values were for Day 1 - 0.88 (95% CI 0.81-0.95), Day 2 – 0.88 (95% CI 




Despite the significant difference in the absolute values of the 3 times points, the Area Under 
the Curve of NT-proBNP at 72 hours was not inferior to the value at 24-48 hours.  
 
 
Figure 3 – Receiver Operating Characteristic Curves and respective Areas Under the Curve 
(AUC) regarding the accuracy of NT-proBNP to diagnose cardioembolic stroke at 24, 48 and 72 
hours after cardioembolic stroke. Areas Under the Curve values can vary between 0 and 1. A 




The number of patients with levels of NT-proBNP above the pre specified cut-off point with a 
high sensitivity for the diagnosis of cardioembolic stroke of 265.5 pg/mL was similar in the 
three time points (Figure 4)[5].  
 
 
Figure 4 – Percentage of all patients, cardioembolic and noncardioembolic patients (including 
undetermined causes) with NT-proBNP values above the cut-off 265.5 pg/mL at day 1, day 2 




In all included stroke patients and in those with cardioembolic and noncardioembolic stroke 
(including undetermined causes), values of NT-proBNP were highest at 24 and 48 hours  after 
ischemic stroke with no statistically significant difference between these two time points and 
had a statistically significant reduction 72h after stroke onset. However the area under the curve 
for the three time points showed similar diagnostic accuracy, which suggests that measurements 
of NT-proBNP in first 72 hours after ischemic stroke are equally useful.  
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Previously, two reports in literature analyzed the variation of NT-proBNP in the first days after 
ischemic stroke [9,10]. Itumur [10] measured NT-proBNP levels in 57 patients at day 1, 3, 5 
and 10 after ischemic stroke. NT-proBNP levels were highest in the first day after ischemic 
stroke and declined significantly from day 3 onwards. However, there was no information about 
day 2 after stroke and individual stroke etiologies were not analyzed. Jensen [9] measured NT-
proBNP levels in 250 patients at day 1, 2, 3, 4 and 5 after ischemic stroke. He found highest 
levels at day 2, with a significant difference between day 1 and day 2. Thereafter there was a 
progressive decreased until day 5. However, there was no information regarding the specific 
etiologies of stroke in these patients or the diagnostic accuracy of NT-proBNP in different time 
points. Patients with atrial fibrillation were excluded from the study.  
In previous reports that studied NT-proBNP or BNP as a possible biomarker of cardioembolic 
stroke, measurements have been done during the first 24 hours after ischemic stroke [6,7,17]. 
The knowledge of an extended time window (72 hours) for the determination of NT-proBNP 
might be useful as a significant proportion of patients does not go to the hospital in the first 24 h 
after stroke onset [18]. This was a major cause of exclusion of patients in our cohort. The 
possibility of an increased time window for NT-proBNP measurements is an important possible 
advantage of the use of NT-proBNP instead of BNP in this setting, as NT-pro BNP is known to 
have an increased half-life [19].  This extended time window of 72 hours, can also have an 
advantage over the user of D-dimers for the diagnosis of cardioembolic stroke, which were 
found to be potentially useful for the diagnosis of cardioembolic stroke in the first 12 hours after 
ischemic stroke [20].  
One limitation of our study was that only three time points with intervals of 24 hours were 
analyzed, eventually if shorter intervals were chosen they would be even more informative.   
The proportion of undetermined stroke etiology in our cohort is similar to the proportion stated 
in other studies – a range from 30 to 40% [21,22]. Although 20 (19.8%) patients presented with 
a clinical lacunar syndrome in only 4 patients it was due to small vessels disease. This was due 
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to a high rate of use of DWI-MRI.  DWI-MRI improves the accuracy of the subtype diagnosis 
of stroke [23]. Most cases of clinical lacunar syndromes not associated to small vessels disease 
were due to large artery or cardiogenic embolic stroke.  
Our observation of higher levels of NT-proBNP in patients with cardioembolic stroke than in 
noncardioembolic stroke is in accordance with previous studies.  The finding of a statistically 
significant difference in NT-proBNP across the 3 times points and the very good value of 
accuracy to diagnose cardioembolic stroke reinforces the idea that NT-proBNP may be used as a 
biomarker of cardioembolic stroke. Serum biomarkers may have an important role in the 
diagnosis of paroxysmal AF, even if ongoing trials of implantable event detectors have 
successful results [24]. To obtain NT-proBNP serum measurements it is necessary to perform a 
venipuncture but this is a less invasive procedure than the implantation of an event detector. 
NT-proBNP measurements are also less expensive and are widely available in most wards and 
emergency departments.  
They could potentially be incorporated in a subclassification of patients with undetermined 
etiology and help in the stratification of patients that could benefit the most from long term 




NT-proBNP levels were highest 24-48 hours after ischemic stroke and started to decline 
thereafter. However the diagnostic accuracy of NT-proBNP to diagnose cardioembolic stroke 
was similar and very good in the first 72 hours after stroke onset.   Our study reinforces that 
BNP may be useful in the identification of patients with cardioembolic stroke and in the 
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Stroke related to atrial fibrillation tends to be severe, with high recurrence and mortality rates 
[1].   Identification of atrial fibrillation in patients with stroke is consequently of paramount 
importance and has therapeutic implications. Atrial fibrillation is usually classified as 
permanent, persistent or paroxysmal.  Paroxysmal atrial fibrillation (pAF) is reported to have 
the same risk as persistent or permanent atrial fibrillation to cause ischemic strokes [2]. 
However identifying pAF can be difficult. Although it is frequently related to structural heart 
disease, about 45% of patients with paroxysmal atrial fibrillation have no echocardiographic 
detectable heart disease [3].  The current available electrophysiological methods (ECG, routine 
telemetry during inpatients admission, Holter monitoring, 30-day event monitoring devices) to 
detect paroxysmal AF all have a low sensitivity [4]. If diagnostic tests fail to identify pAF, 
stroke etiology may be incorrectly classified as cryptogenic (undetermined etiology) [5]. 
Alternative ways to detect paroxysmal atrial fibrillation in cryptogenic stroke should be 
considered. Recent studies suggest that NT-proBNP (N-terminal probrain natriuretic peptide), a 
peptide produced by the heart, may be useful to identify cardioembolic stroke associated with 
AF [6,7,8]. In a previous study, NT-proBNP had good accuracy in predicting ischemic stroke of 
cardioembolic cause associated with atrial fibrillation. Two cut-off points – 265.5 pg/mL and 
912.0 pg/ml, associated with a high negative and high positive predictive value for the diagnosis 
of AF (97.2% and 90.9 %, respectively) were obtained [6] 
In this study we aimed to validate the previous defined cut-off values of serum NT-proBNP for 









Observational, cross-sectional study 
 
Study Population: 
Consecutive patients admitted to the Stroke Unit of the Neurology Department of the Hospital 
de Santa Maria from December 2009 to June 2010, from September 2010 to December 2010 
and from April 2011 to March 2012. In order to be included patients had to have an ischemic 
stroke (according to the World Health Organization criteria [9]) or transient ischemic attack 
(TIA) [10] and be admitted to the stroke unit within 72 hours of stroke onset. Patients were 
excluded if they had acute renal failure or chronic renal insufficiency (glomerular filtration rate 
glomerular determined by the equation of Cockcroft-Gault, less than 90 mL / min, hemodialysis 
or peritoneal dialysis).  
 
Sample size calculation: 
To validate the cut-off values of NT-proBNP in patients with a defined stroke etiology, taking 
in account the previous evaluated sensitivity of 94.4% of the cut-off value of 265.5 pg/mL and 
the specificity of 97% of the cut-off value of 912.0 pg/mL [6], in a population where the 
prevalence of atrial fibrillation is 0.30, with a required lower 95% confidence limit >0.8 with 
0.95 probability, a number of 50 patients  and 116 controls was required (total 166 patients with 







Patients with ischemic stroke or transient ischemic attack (TIA) were admitted to the Stroke 
Unit. In patients who met the study criteria, 4 ml of blood were drawn from a peripheral vein 
within 72 hours of stroke onset. Blood samples were immediately taken to the Clinical 
Pathology Department. Blood samples were centrifuged at 1600 g during 15 minutes. NT-
proBNP levels were measured by an electrochemiluminescence assay using the Elecsys 2010 
immunoassay analyzer (Roche Diagnostics, Mannheim, Germany) [12].  
Information on demography, vascular risk factors, previous AF and admission National 
Institutes of Health Stroke Scale (NIHSS) score [13] was collected. Etiological workup included 
in all patients a complete blood count, erythrocyte sedimentation rate, hepatic and renal 
function, glucose and lipid levels, protein electrophoresis and coagulation studies. In patients 
<55 years old, workup also included autoantibodies, lupus anticoagulant, anticardiolipin 
antibodies, C and S protein, antithrombin III, fibrinogen levels, HIV 1 and 2, Hepatitis B and C 
serologies.  In all patients a brain-CT or MRI (71% MRI), transcranial Doppler, carotid and 
vertebral duplex scanning and Transthoracic Echocardiographic examination (M-mode, two 
dimensional and Doppler study) were performed. The following parameters were registered: 
atrial dimensions (atrial dilatation was defined as an end-systolic diameter >40 mm) [14], left 
atrial spontaneous echo contrast, intracardiac thrombus, left ventricular ejection fraction 
(LVEF), persistence of patent foramen ovale (PFO), hypokinetic ventricular wall regions, 
diastolic dysfunction [15] and left ventricular hypertrophy. Systolic dysfunction was defined as 
a LVEF < 50%. In all patients <55 years old (18.7% of total patients), contrast transcranial 
Doppler with agitated saline was done to look for a right left shunt and transesophageal 
echocardiogram were performed. To detect pAF at least two ECGs and one 24-hours Holter 
monitoring were performed within the first week of the presenting event. Stroke etiological 
classification was done by stroke neurologists using the TOAST criteria, blind to NT-proBNP 
determinations [16]. If patients had a past history of atrial fibrillation, stroke was considered to 
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be cardioembolic if no other finding was disclosed.  Atrial fibrillation was defined as a 
dysrhythmia with at least 30 continuous seconds [17] with no detectable P waves and no other 
diagnosis. 
 The study was approved by the Ethic Committee of our hospital. A signed informed consent 
was obtained from the patient or from a relative or legal representative. 
 
Statistics: 
A descriptive statistical analysis of demographic and vascular risk factors of all patients with 
ischemic stroke, atrial fibrillation and non-atrial fibrillation was performed. Data distribution 
was evaluated using histograms and a one sample Kolmogorov-Smirnov test. For normally 
distributed data, results were presented with mean and standard deviation (SD). For non-
normally distributed data, median and interquartile ranges (IQR) were defined. For comparison 
between groups the chi-square test, Fisher exact test, Mann-Whitney test or T-test were used as 
appropriate. 
Patients with a defined stroke etiology at the time of hospital discharge were used to construct a 
Receiver Operating Characteristic (ROC) curve to determine the accuracy of NT-proBNP for 
the diagnosis of atrial fibrillation. In this case the gold standard for the diagnosis of atrial 
fibrillation was a known and established diagnosis based on a previous ECG or Holter.  From 
this curve, the Area Under the Curve (c-statistics), the sensitivity and specificity - with the 
respective confidence intervals of the established cut-off points was calculated [6].  The cut-off 
points of NT-proBNP of 265.5 and 912.0 pg/mL were chosen in a previous study due to their 
high sensitivity (94.4%) and specificity (97.9%) respectively [6]. A multivariate analysis was 
performed using a logistic regression model, to assess the independent relationship of logNT-
proBNP with atrial fibrillation controlling for previously known confounders – age, sex, atrial 
dilatation, left ventricular hypertrophy and systolic dysfunction. Variables were included in the 
logistic regression model as predictors based on prior knowledge and also based on the previous 
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study of the association between the different variables and outcome or exposure. Results are 
presented as odds ratios and 95% confidence intervals (CI).  
Statistical analyses were done using the SPSS 19.0 and SAS 9.2 for windows. Significance level 
was set at p=0.05. 
This study followed the Standards for Reporting of Diagnostic Accuracy (STARD) statement 




264 patients were included with a mean age of  63.8 (SD 12.2) years (Figure 1).  
 




Twenty-five patients had a TIA (9.5%). In 184 patients a specific stroke etiology was 
established. The specific stroke etiologies were: 94 cardioembolic (51.1%), 57 large vessels 
disease (31.0%), 17 small vessels disease (9.2%), 6 undetermined/more than 1 possible etiology 
(3.3%). Among cardioembolic strokes 52 were due to atrial fibrillation, 4 due to a patent 
foramen ovale plus atrial septum aneurysm, 19 due to patent foramen ovale, 11 due to 
hypokinetic/akinetic left ventricular segments, 3 due to endocarditis, 1 due to mitral valve 
prolapse, 2 due to a mechanical valvular prosthesis, 1 due to dilated cardiomyopathy and 1 due 
to a heart tumor.  Three of the 6 patients with more than a possible stroke etiology had both 
atrial fibrillation and an ipsilateral carotid stenosis superior to 50%. In total 55 patients had 
atrial fibrillation. Patients with atrial fibrillation were more frequently older, female, with atrial 
dilatation and higher admission NIHSS scores (Table 1). Patients without atrial fibrillation were 
more frequently smokers. 
 AF  (n=55) No AF  (n=129) p-value 
NT-proBNP (pg/dL) median (IQR)                    1777 (2710) 138 (332) <0.0001 
TIA n (%) 2 (3.6) 18 (14.0) 0.04 
Age, years  mean (SD) 70.3  (7.8) 58.6 (12.7) <0.0001 
Female  n (%) 31 (56.4) 48 (37.2) 0.02 
Hypertension  n (%) 36 (65.5) 91 (70.5) 0.49 
Diabetes  n (%) 10 (18.2) 37 (28.7) 0.14 
Dyslipidemia n (%) 29 (52.7) 54 (41.9) 0.18 
Current Smoker  n (%) 4 (7.3) 39 (30.2) 0.001 
Previous MI or angina n (%) 12 (21.8) 18 (14.0) 0.19 
Previous stroke or TIA n (%) 21 (38.2) 30 (23.3) 0.04 
Hgb (g/dL)  mean ( SD) 14.0 (1.7) 13.9 (1.8) 0.71 
Weight (Kg) median  (IQR)  74.1 (19.5) 75.0 (14.6) 0.22 
ACEI  n (%) 16 (29.1) 33 (25.6) 0.62 
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ARB  n (%) 11 (20.0) 22 (17.1) 0.63 
B-blocker  n (%) 23 (41.8) 23 (17.8) 0.001 
Admission NIHSS  median (IQR) 13 (12) 4 (8) <0.0001 
Anterior circulation stroke  n (%) 53 (96.4) 89 (70.6) <0.0001 
Atrial dilatation  n (%)   42 (76.4) 31 (24.0) <0.0001 
LV hypertrophy  n (%)  21 (38.2) 33 (25.6) 0.09 
Systolic dysfunction  n (%) 10 (18.2) 14 (10.9) 0.18 
Diastolic dysfunction  n (%) 
(n=115) 
6 (21.4) 47 (54.0) 0.003 
Segmental LV hypokinesia or 
akinesia  n (%) 
10 (18.2) 17 (13.2) 0.38 
 
Table 1 – Characteristics of patients with a known stroke etiology, with or without atrial 
fibrillation;  AF – atrial fibrillation, ACEI – angiotensin converting enzyme inhibitors, ARB - 
angiotensin receptor blockers, Hgb- hemoglobin,  IQR – interquartile range,   LV – left 
ventricular, MI – myocardial infarction, SD – standard deviation, TIA – transient ischemic 
attack;  Systolic dysfunction was defined as a left ventricular ejection fraction < 50%,  
 
NT-proBNP levels followed a right skewed distribution. Levels of NT-proBNP were higher in 





Figure 2 – NT-proBNP (pg/mL) levels in patients with a specific stroke etiology, with or 
without atrial fibrillation (AF)  
Correlation of values of NT-proBNP levels with vascular risk factors and echocardiographic 
parameters are shown in table 2. 
        NT-proBNP cut-off   265.5 pg/mL 
Phi coefficient                                 p value 
 
Sex   0.111                                                0.131 
Hypertension   0.066                                                0.370 
Diabetes Mellitus   0.031                                                0.674 
Atrial fibrillation   0.646                                              <0.001 
Atrial enlargement   0.529                                              <0.001 
Left ventricular systolic dysfunction   0.319                                              <0.001 
Left ventricular hypertrophy    0.232                                                0.003 
 




Using multivariate analysis logNT-proBNP (logarithm transformation of NT-proBNP) was 
independently associated to atrial fibrillation (OR – 2.65, 95% CI 1.57-4.45; p<0.0001), after 
adjusting for age, sex, left ventricular hypertrophy, atrial dilatation and systolic dysfunction 




                            Atrial fibrillation 
          OR                   95% CI                p-value        
Log NT-proBNP 3.031 1.972-4.658 <0.0001 
Female 4.949 2.047-11-96 <0.0001 
Atrial dilatation 4.390 1.811-10.462 0.001 
Age  1.054 1.008-1.103 0.021 
Left ventricular hypertrophy 0.775 0.329-1.823 0.559 
Systolic dysfunction  0.531 .0129-2.180 0.380 
 
Table 3  - Results of the logistic regression  
 
Adding admission NIHSS scores to the model did not change the significance of the association 
between logNT-proBNP and atrial fibrillation. Among patients with a specific stroke etiology, 
the Area Under the Curve (AUC) of the ROC curve of NT-proBNP for the diagnosis of atrial 
fibrillation was excellent - 0.91, 95% CI (0.87-0.95) (Figure 3). An AUC of 1 means that the 





Figure 3 – ROC curve of NT-proBNP for the diagnosis of atrial fibrillation (AF) in patients with 
known stroke etiology  
 
The previously defined cut-off of  265.5 pg/ml had a sensitivity of 100% 95% CI (93.5-100%), 
a specificity of 70.5% (62.2-77.7%), a positive predictive value of 59.1% 95% CI (48.5-69.2%) 
and a negative predictive value of 100% 95% CI (96.0-100%). In this study, the cut-off value of 
304 pg/ml had the same sensitivity 100% 95%CI (93.5-100%)  with a higher specificity of 
71.3% 95% CI(62.7-78.9%), positive predictive value of 59.8% 95% CI (49.0-69.9%) and 
negative predictive value of 100% 95% CI (96-100%). The cut-off point of 912 pg/ml had a 
sensitivity of 81.8% 95% CI (69.7-89.8%),  a specificity of 87.5% 95% CI (80.8-92.2%), a 
positive predictive value of 73.8% 95% CI (60.9-84.2%) and a negative predictive value of 




Figure 4 - Distribution of patients with a specific stroke etiology according to the defined cut-




This was the first study in which previously defined NT-proBNP cut-off levels for the diagnosis 
of cardioembolic stroke associated to atrial fibrillation were evaluated. In order to use NT-
proBNP as a biomarker of cardioembolic stroke it is necessary to demonstrate the internal and 
external validity of the cut-off points. The initial study tends to optimize the defined cut-off 
points, therefore the sensitivity and specificity of the cut-off points tends to fall in validation 
studies. In order to validate the cut-off points a sample size was calculated. When the cut-off 
points were evaluated in this second study their high sensitivity and specificity was maintained. 
This is a point in favor of their external validity, however the cut-off points should be further 
validated in studies involving patients from different centers and with different baseline 
characteristics, to confirm if these results apply to other patient groups. The normal range of 
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NT-proBNP varies on the basis of age and gender, making it difficult to define a true reference 
range. Nevertheless, normal ranges of NT-proBNP fall well below our defined cut-off points 
levels of NT-proBNP level for patients with atrial fibrillation.  
As the question if NT-proBNP was an independent predictor of atrial fibrillation or if the 
increase of NT-proBNP was just do to concomitant systolic or diastolic dysfunction aroused it 
was necessary to perform a multivariate analysis. The variables used in the logistic regression 
model included factors known to be possible confounders, this is related to both NT-proBNP 
increase and to atrial fibrillation. After controlling for age, sex, atrial dilatation, left ventricular 
hypertrophy and systolic dysfunction, NT-proBNP was independently associated to atrial 
fibrillation. Hypertension and diastolic dysfunction were not put into the model because they are 
highly correlated to the other variables (left ventricular hypertrophy and systolic dysfunction). 
The result that NT-proBNP is an independent predictor of atrial fibrillation after controlling for 
systolic dysfunction and atrial enlargement is in agreement with previous studies. One study 
demonstrates that NT-proBNP level was directly and proportionately associated with AF burden 
as assessed by continuous ambulatory rhythm monitoring and that this association was 
independent of other factors known to affect NT-proBNP. There are recent publications that 
suggest that NT-proBNP is a predictor of atrial fibrillation following cardiac surgery [21,22,23] 
and successful cardioversion [24]. The results support the notion that atrial fibrillation is an 
additional, independent cause of elevated NT-proBNP levels and should be part of the 
differential diagnosis when increased levels are present.   
The logistic regression model shows that several of the included variables were independently 
related to atrial fibrillation. From the results of the logistic regression a predictive score 
containing clinical, laboratorial and echocardiographic characteristics could be derived, 
nevertheless this was not an aim of this specific study. We intended to determine a cut-off point 
that could increase the physician suspicion of atrial fibrillation and guide the execution of 
further electrophysiological tests to confirm the diagnosis of paroxysmal atrial fibrillation. The 
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Alternative ways to detect paroxysmal atrial fibrillation in cryptogenic stroke should be 
considered. Recent studies suggest that NT-proBNP (N-terminal probrain natriuretic peptide), a 
peptide produced by the heart, may be useful to identify cardioembolic stroke associated with 
AF [1,2,3].  
Elevated NT-proBNP is also a marker for patients at high risk of atrial fibrillation. In the 
Cardiovascular Health Study, a large cohort study of elderly people followed for cardiovascular 
outcomes, the risk of developing incident atrial fibrillation was increased in those with elevated 
NT-proBNP, but not during the initial 2 years [4].  
In a previous study, NT-proBNP had good accuracy in predicting ischemic stroke of 
cardioembolic cause associated with atrial fibrillation. Two cut-off points – 265.5 pg/mL and 
912.0 pg/ml, associated with a high negative and high positive predictive value for the diagnosis 
of AF (97.2% and 90.9 %, respectively) were obtained [1] 
In this study we aimed to determine if  NT-proBNP could identify paroxysmal AF in patients 












Consecutive patients admitted to the Stroke Unit of the Neurology Department of the Hospital 
de Santa Maria, Lisboa, from December 2009 to June 2010, from September 2010 to December 
2010 and from April 2011 to March 2012. In order to be included patients had to have an 
ischemic stroke (according to the World Health Organization criteria [5]) or transient ischemic 
attack (TIA) [6] and be admitted to the stroke unit within 72 hours of stroke onset. Patients were 
excluded if they had acute renal failure or chronic renal insufficiency (glomerular filtration rate 
glomerular determined by the equation of Cockcroft-Gault, less than 90 mL / min, hemodialysis 
or peritoneal dialysis). 
 
Sample size calculation: 
Taking into account the information from a previous publication [1] the mean  of  NT-proBNP 
levels in patients with an cardioembolic ischemic stroke was 491.6 pg/mL with a standard 
deviation of 420.96 (n=28) and the mean in patients with non-cardioembolic stroke was 124.7 
pg/mL with a standard deviation of 69.55 (n=38). With a power of 95% and an alpha of 0.05 to 
show a statistically significant difference between groups, a total sample size of 40 patients with 
undetermined stroke etiology. Assuming a percentage of cryptogenic strokes of 16%, a cohort 
of 250 patients was needed.  
 
Clinical Protocol: 
Patients with ischemic stroke or transient ischemic attack (TIA) were admitted to the Stroke 
Unit. In patients who met the study criteria, 4 ml of blood were drawn from a peripheral vein 
within 72 hours of stroke onset. Blood samples were immediately taken to the Clinical 
Pathology Department. Blood samples were centrifuged at 1600 g during 15 minutes. NT-
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proBNP levels were measured by an electrochemiluminescence assay using the Elecsys 2010 
immunoassay analyzer (Roche Diagnostics, Mannheim, Germany) [7].  
Information on demography, vascular risk factors, previous AF and admission National 
Institutes of Health Stroke Scale (NIHSS) score [8] was collected. Etiological workup included 
in all patients a complete blood count, erythrocyte sedimentation rate, hepatic and renal 
function, glucose and lipid levels, protein electrophoresis and coagulation studies. In patients 
<55 years old, workup also included autoantibodies, lupus anticoagulant, anticardiolipin 
antibodies, C and S protein, antithrombin III, fibrinogen levels, HIV 1 and 2, Hepatitis B and C 
serologies.  In all patients a brain-CT or MRI (71% MRI), transcranial Doppler, carotid and 
vertebral duplex scanning and Transthoracic Echocardiographic examination (M-mode, two 
dimensional and Doppler study) were performed. The following parameters were registered: 
atrial dimensions (atrial dilatation was defined as an end-systolic diameter >40 mm) [9], left 
atrial spontaneous echo contrast, intracardiac thrombus, left ventricular ejection fraction 
(LVEF), persistence of patent foramen ovale (PFO), hypokinetic ventricular wall regions, 
diastolic dysfunction [10] and left ventricular hypertrophy. Systolic dysfunction was defined as 
a LVEF < 50%. In all patients <55 years old (18.7% of total patients), contrast transcranial 
Doppler with agitated saline was done to look for a right left shunt and transesophageal 
echocardiogram were performed. To detect pAF at least two ECGs and one 24-hours Holter 
monitoring were performed within the first week of the presenting event. Stroke etiological 
classification was done by stroke neurologists using the TOAST criteria, blind to NT-proBNP 
determinations [11]. If patients had a past history of atrial fibrillation, stroke was considered to 
be cardioembolic if no other finding was disclosed.  Patients with a cryptogenic stroke were 
followed as outpatients.  During follow-up,  in all patients, after hospital discharge, 
independently of NT-proBNP values, serial 24 hour Holter monitoring was performed within 
three and six months (if the previous monitoring was unremarkable) to look for paroxysmal 
atrial fibrillation and was used as reference standard. Atrial fibrillation was defined as a 
dysrhythmia with at least 30 continuous seconds [12] with no detectable P waves and no other 
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diagnosis. The study was approved by the Ethic Committee of our hospital. A signed informed 
consent was obtained from the patient or from a relative or legal representative. 
 
Statistics 
A descriptive statistical analysis of demographic and vascular risk factors of all patients with 
ischemic stroke, atrial fibrillation and non-atrial fibrillation was performed. Data distribution was 
evaluated using histograms and a one sample Kolmogorov-Smirnov test. For normally distributed 
data, results were presented with mean and standard deviation (SD). For non-normally 
distributed data, median and interquartile ranges (IQR) were defined. For comparison between 
groups the chi-square test, Fisher exact test, Mann-Whitney test or T-test were used as appropriate. 
To evaluate the diagnostic accuracy of NT-proBNP to diagnose paroxysmal atrial fibrillation in 
patients with cryptogenic stroke, Receiver Operating Characteristic curves were determined. 
The area under the curve (c-statistics) was determined.  
Statistical analyses were done using the SPSS 19.0 and SAS 9.2 for windows. Significance level 




The characteristics of the 264 patients that were included in this cohort were presented in the 
previous chapter. Among the 264 patients, 80 patients had a cryptogenic stroke at the time of 
hospital discharge. Three patients died within the first month of follow-up. These patients had 
NT-proBNP values of 1066, 1259 and 2426 pg/mL. In 17 (21.3%) paroxysmal atrial fibrillation 
was found during follow-up. In 14 patients the identification of paroxysmal atrial fibrillation 
was done within the first month after stroke onset. Patients in whom paroxysmal atrial 
fibrillation was subsequently found were older and had higher admission NIHSS scores (Table 1). 
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 AF  (n=17) No AF  (n=63) p-value 
NT-proBNP (pg/dL)  median (IQR) 883 (817) 214 (367) <0.0001 
TIA n (%) 0 (0) 5 (7.9) 0.58 
Age, years  median (IQR) 74 (7) 68 (15) 0.006 
Female  n (%) 13 (76.5) 25 (39.7) 0.12 
Hypertension  n (%) 12 (70.6) 45 (71.4) 0.99 
Diabetes  n (%) 4 (23.5) 19 (30.2) 0.77 
Dyslipidemia  n (%) 8 (47.1) 18 (28.6) 0.16 
Current Smoker  n (%)  0 (0) 7 (11.1) 0.34 
Previous MI or angina  n (%) 2 (11.8) 7 (11.1) 0.99 
Previous stroke or TIA  n (%) 3 (17.6) 15 (23.8) 0.75 
Hgb (g/dL) mean (SD) 13.4 (1.0) 13.7 (1.4) 0.42 
Weight (Kg) median (IQR)  70 (11.9) 74 (12.5) 0.22 
ACEI  n (%) 6 (35.3) 11 (17.5) 0.18 
ARB   n (%) 4 (23.5) 15 (23.8) 0.99 
B-blocker  n (%) 7 (41.2) 12 (19.0) 0.10 
Admission NIHSS  median (IQR) 13 (11) 7 (8) 0.04 
Anterior circulation stroke  n (%) 16 (94.1) 48 (76.2) 0.17 
Atrial dilatation  n (%)  10 (58.8) 21 (33.3) 0.06 
LV hypertrophy  n (%)  4 (23.5) 24 (38.1) 0.26 
Systolic dysfunction  n (%) 1 (5.9) 0 (0) 0.21 
Diastolic dysfunction  n (%) 
(n=60)  
7 (53.8) 27 (57.4) 0.82 
 
Table 1 – Characteristics of patients with cryptogenic stroke at the time of hospital discharge; 
AF – atrial fibrillation, ACEI – angiotensin converting enzyme inhibitors, ARB - angiotensin 
receptor blockers, Hgb- hemoglobin,  IQR – interquartile range,   LV – left ventricular, MI – 
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myocardial infarction, SD – standard deviation, TIA – transient ischemic attack; Systolic 
dysfunction was defined as a left ventricular ejection fraction < 50% 
 
NT-proBNP values at admission were higher in cryptogenic stroke patients in whom 
paroxysmal atrial fibrillation was later found than in patients without detection of atrial 
fibrillation (Figure 1). 
 
Figure 1 – NT-proBNP (pg/mL) levels in patients with initial cryptogenic stroke with or without 
later detection of paroxysmal atrial fibrillation (pAF) 
 
 In patients with cryptogenic stroke, the cut-off point of 265.5 pg/ml had a sensitivity of 88.2% 
95% CI (65.7-96.7%),  a specificity of 61.9% 95% CI (49.6-72.9%), a positive predictive value 
of 38.5% 95% CI (23.4-55.4%) and a negative predictive value of 95.1% (83.4%-99.3%)  for 
the diagnosis of paroxysmal atrial fibrillation. The cut-off point of 912 pg/mL had a sensitivity 
of 47.1% 95% CI (26.2-69.0%) and a specificity of 88.9% 95% CI (78.8-94.5%), a positive 
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predictive value of 53.3% 95%CI (26.7-78.7%) and a negative predictive value of 86.2% 
95%CI (75.3-93.5%) (Figure 2).  
 
Figure 2 – Distribution of patients according to the defined cut-off point and the presence or not 
of atrial fibrillation (AF)  
 
The AUC of the ROC curve of NT-proBNP for the diagnosis of paroxysmal atrial fibrillation in 







Figure 3 – ROC curve of NT-proBNP for the diagnosis of paroxysmal atrial fibrillation in 




NT-proBNP levels at the time of stroke onset were helpful to identify paroxysmal atrial 
fibrillation in the follow-up of patients with an undetermined stroke etiology. The previously 
defined cut-off points of 265.5pg/mL and 912.0 pg/mL had a high sensitivity and specificity for 
the diagnosis of paroxysmal AF in patients with cryptogenic stroke (88.2 and 88.9% 
respectively). This is the first study in which NT-proBNP accuracy to diagnose paroxysmal 
atrial fibrillation was analyzed in cryptogenic stroke.  
Normally atrial and ventricle myocytes express BNP genes that code for ProBNP. ProBNP is 
stored in atrial granules. Following the hemodynamic effect of atrial fibrillation, the precursor 
molecules, pre-produced proBNP, that are stored in atrial myocites are secreted as BNP and NT-
proBNP [14], leading to the high levels of NT-proBNP. Therefore NT-proBNP levels could 
remain elevated in serum during sinus rhythm after a short course of paroxysmal atrial 
fibrillation. Probably patients with cryptogenic stroke in which later atrial fibrillation were 
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found had an episode of atrial fibrillation in close vicinity to stroke onset that caused an increase 
in NT-proBNP levels. Although they returned to a sinus rhythm, NT-proBNP remained elevated 
as a consequence of the paroxysmal episode of atrial fibrillation. NT-proBNP has been shown to 
be a remarkable predictor of incident atrial fibrillation in the general population, independently 
of any other previously described risk factor [15].  
Although in this study median levels of NT-proBNP in patients with paroxysmal atrial 
fibrillation were lower than the median levels of NT-proBNP obtained in patients with 
persistent or permanent atrial fibrillation in the initially exploratory study [1] , the cut-off points 
still maintained a high sensitivity and specificity. A previous study also found higher levels of 
NT-proBNP in patients with persistent/permanent atrial fibrillation as compared with 
paroxysmal atrial fibrillation [4]. 
One report [16] evaluated  NT-proBNP as a predictor of atrial fibrillation in patients with stroke 
in sinus rhythm in general and found  that it had a reasonable accuracy for this diagnosis (AUC 
– 0.638 (95%CI 0.531-0.744)).  Differences between this study and ours may explain the 
dissimilar result: 
 1) In our study we evaluated the diagnostic accuracy of NT-proBNP to diagnose atrial 
fibrillation in patients with cryptogenic stroke, while the study reported by Wachter et al [17] 
evaluated NT-proBNP accuracy to diagnose atrial fibrillation in stroke patients with sinus 
rhythm. The most clinically relevant question is which patients with cryptogenic stroke have 
atrial fibrillation. In the study of Wachter et al, patients with an already established 
cardioembolic etiology were included in the group of patients further evaluated for atrial 
fibrillation [17]. The cardioembolic etiologies of these patients were not included in the report 
[17]. These already known cardioembolic etiologies may have contributed to increased NT-
proBNP levels in these patients. 
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2)  We used different methods and a longer time periods to look for atrial fibrillation which 
might have influenced the results and lead to a higher rate of detection of atrial fibrillation (12.7 
versus 21.3% in our study). 
3) In our study we preferred to use NT-proBNP instead of BNP because NT-proBNP is known 
to have an increased half-life [14] and therefore may extend the time window during which it 
can be determined after stroke onset.  This is clinically important because a sizable fraction of 
patients do not attend the emergency department in the first 24 hours after stroke onset 
Strengths of this study include the following:  
1) It is the first study that evaluated the accuracy of NT-proBNP to diagnose atrial fibrillation in 
patients with cryptogenic stroke. For this a follow up time of six months was used;  
2) It was designed to take place in a clinical setting similar to the one in which it could be 
applied;  
3) This study showed that the cut-off values for NT-proBNP that were defined previously were 
corroborated as being very sensitive and specific for paroxysmal atrial fibrillation; 
 4) The STARD criteria were followed.  
Limitations of this study include the time points during the follow up after ischemic stroke that 
were chosen to look for atrial fibrillation. It is possible that in some patients with paroxysmal 
atrial fibrillation this arrhythmia was not diagnosed with the currently used diagnostic 
examinations. However a low detection rate would only contribute to decrease the sensitivity 
and specificity of the chosen points. Therefore, specificity might have been underestimated in 
this study. In patients with cryptogenic stroke the diagnosis of atrial fibrillation is particularly 
important as it changes the therapeutic decision, leading to the prescription of anticoagulants 
instead of antiplatelet agents. Cryptogenic stroke patients are many times submitted to extensive 
and costly electrophysiological investigations. NT-proBNP measurements could be helpful to 
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guide or eliminate further ECG, Holter or other electrophysiologic monitoring in patients with 
stroke. In patients with cryptogenic strokes, with uneventful echocardiograms an increase in 





NT-proBNP had good accuracy to predict paroxysmal atrial fibrillation in patients with 
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Natriuretic peptides such as BNP and NT-proBNP may be useful biomarkers for occult 
paroxysmal atrial fibrillation in patients with ischemic stroke of undetermined etiology. Using a 
population based study, we related baseline BNP levels at the time of a first transient ischemic 
attack or ischemic stroke to etiology in patients who had a recurrent ischemic stroke during 
follow-up.  
We aimed to determine if patients with an undetermined ischemic stroke etiology in which latter 









Patients included in the Oxford Vascular Study (OXVASC) from 2002 to 2009 due to an initial 
ischemic stroke with a late recurrence (more than 90 days after the initial stroke). [1] The 
OXVASC study population consists of 91 106 individuals, registered with 63 family physicians 
in nine general medical practices in Oxfordshire, United Kingdom. In the United Kingdom, 
general practices provide primary health care for registered individuals and hold a lifelong 
record of all medical consultations (from the National Health Service and private health care), 
and details of treatments, blood pressure, and investigations. All participating practices held 
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accurate patient registers, and allowed regular searches of their computerized diagnostic coding 
systems.  
In order to be included patients had to have: 
- Evidence of an initial ischemic stroke according to the World Health Organization 
definition  [2] and confirmation with a Head-CT or Brain-MRI 
-        Blood analysis at the time of the index stroke 
- ECG at the time of index stroke  
- Performance of at least one extra cranial vascular imaging  
- At least one late ischemic recurrence (> 90 days) 
Patients were excluded from the study if they had:             
- Heart failure at the time of index stroke (modified Framingham criteria for heart failure 
(e) or injection fraction below 50% in a transthoracic echocardiogram) 
- Chronic renal failure at the time of index stroke (glomerular filtration rate determined by 
the Cockcroft-Gault equation below 90 mL/min, hemodialysis or peritoneal dialysis) 
Demographic variables, patients’ personal history of hypertension, diabetes mellitus, atrial 
fibrillation, anemia, blood pressure lowering medication were recorded. Ischemic stroke 
etiology classification was done according to the TOAST classification. 
 
Study design  
We analyzed all patients in the OXVASC (2002-2009) with an transient ischemic attack  or 
ischemic stroke who had a recurrent stroke more than 90-days after the initial event.  
Stroke etiology was classified according to the data pertaining to the initial event using the 
TOAST criteria. Recurrences classified as undetermined etiology by TOAST were also 
classified (blind to BNP results) as probably cardioembolic versus probably non-cardioembolic 
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based on clinical and imaging criteria. Stroke were further classified has probably 
cardioembolic when there were large territorial infarcts, with a complete investigation. The 
definition of undetermined stroke was redefined for this study. Patients were considered as 
having had an undetermined stroke etiology when they had a normal complete investigation.  
Complete investigation was defined to be composed by blood analysis, ECG, Head CT or Brain 
MRI and at least one extracranial vascular imaging.  Patients without a complete investigation 
were excluded. Patient with more than one possible etiology were classified in a separate group. 
Patients were treated at the time of stroke onset, concerning stroke secondary prevention, with 
the best medical therapy available at the time. Blood was drawn at the time of the first event and 
stored. The stored blood was used to determine BNP levels through an ELISA method.  
 
Statistical analysis  
A descriptive statistical analysis of demographic and vascular risk factors of all patients with 
ischemic stroke was performed. Data distribution was evaluated using histograms and a one 
sample Kolmogorov-Smirnov test. For normally distributed data, results were presented with 
mean and standard deviation (SD). For non-normally distributed data, median and interquartile 
ranges (IQR) were defined. For comparison between groups the chi-square test, Fisher exact 




Ninety-nine patients had a recurrent stroke during follow-up. Their mean age was 77.3 years, 
with a minimum of 50 years, and a maximum of 80 years. Forty-seven were men. Median time 
to first recurrence was 1.45 years with a minimum of 0.29 years and a maximum of 6.8 years. 
Mean time of blood storage was 5.8 years with a standard deviation of 1.8 years. 




Table 1 – TOAST classification of first and late events, AF – atrial fibrillation, CE – 
cardioembolic, HF – heart failure, Hyp – hypokinesia, LA – large vessels disease, MI – 
myocardial infarction, SMV – small vessels disease, UND – undetermined 
 
 
Patients with known atrial fibrillation at the initial stroke (n=32) had a higher (p<0.001) median 
(IQR) BNP (1988; 788-3542 pg/mL) than those without atrial fibrillation (248; 97-1259 
pg/mL).   
Among patients with initially undetermined stroke etiology, those in whom atrial fibrillation 
was discovered at the time of the recurrent stroke (n=19) had had higher (p=0.05) baseline BNP 
(584;294-1467 pg/mL) than those (n=10) with a recurrent stroke of other definite etiology 





Figure 1 - Serum concentration of BNP at the initial event in patients that initially had an 
undetermined etiology and latter had a recurrence with atrial fibrillation versus patients that had 
a definite non-cardioembolic recurrence 
 
The same was true in patients with initially undetermined stroke etiology with later atrial 
fibrillation or probable cardioembolic recurrence (n=27) versus those (n=24) with probable or 






Figure 2 – Serum concentration of the BNP at the initial event in patients that initially had an 
undetermined etiology and latter had recurrence with AF or probable cardioembolic versus a 




Natriuretic peptides may be useful as biomarkers of cardioembolic stroke related to paroxysmal 
atrial fibrillation. Theoretically NT-proBNP measurements may have advantages over BNP due 
to NT-proBNP increased half-life [4]. In this study, we aimed to determine in a population 
based study if patients with an initially undetermined stroke etiology that latter had a recurrent 
stroke etiology in which atrial fibrillation was found had increased levels of BNP at the time of 
the index stroke. There are some limitations in this study regarding the exams that were done to 
classify stroke etiology, not all patients did echocardiograms or Holter examinations, 
nevertheless patients with Transient Ischemic attack or stroke of initially undetermined etiology 
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in whom atrial fibrillation was detected at the time of subsequent recurrent stroke had had high 
BNP levels at the time of the first event. Results are in agreement with a recent study, in the 
general population, that found that elevated plasma Troponin and NT-proBNP concentrations 
were associated with increased risk of cardioembolic and other nonlacunar ischemic strokes [5]. 
NT-proBNP level was shown to be a predictor of future development of atrial fibrillation, 





Patients with Transient Ischemic attack or stroke of initially undetermined etiology in whom 
atrial fibrillation was detected at the time of subsequent recurrent stroke had had high BNP 
levels at the time of the first event. BNP may be useful in identification of patients with 
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Frequently after an extensive investigation it is not possible to establish an ischemic stroke 
etiology and strokes end up being classified as undetermined.  The diagnostic of an 
undetermined stroke etiology is many times frustrating for both physician and family. Correctly 
diagnosing a paroxysmal atrial fibrillation in these circumstances is important because it leads 
to a change in treatment. Anticoagulants have been shown to be superior to antiplatelets in the 
secondary prevention of stroke related to atrial fibrillation. To start anticoagulation in all 
patients with an undetermined stroke etiology is not a solution has it has been shown that for 
other ischemic strokes the hemorrhagic risk outweighs the benefit [1].  
As the currently available methods to diagnose paroxysmal atrial fibrillation have a low 
sensitivity it is important to consider new ways to diagnose this dysrhythmia in the setting of 
ischemic stroke. Biomarkers could be an useful alternative. Natriuretic peptides, specifically 
NT-proBNP a peptide produced by both the hypothalamus and the heart has been shown to be 
useful in this context. NT-proBNP is produced mainly by the heart, both the atria and ventricles 
can produce it. It is synthetized and stored in granules. After an episode of atrial fibrillation the 
pressure and volume overload may lead to the release of the stored granules to the circulation 
leading to a rise in serum NT-proBNP levels. Studies have shown an increase in NT-proBNP in 
atrial fibrillation with a return to baseline levels after conversion to sinus rhythm. Therefore NT-
proBNP could potentially be used as a biomarker of cardioembolic stroke. As it was also 
produced by the hypothalamus it was necessary to investigate if levels of NT-proBNP differed 
in patients with carotid versus vertebro-basilar stroke and also according to the area of stroke 
infarct. We conducted an initial study that showed that the increase of NT-proBNP levels did no 
correlate with both of these parameters [2].  We measured NT-proBNP levels in patients with 
cardioembolic versus non-cardioembolic stroke and reported increased levels in patients with 
cardioembolic stroke. NT-proBNP had a very good accuracy to diagnose cardioembolic stroke, 
namely related to atrial fibrillation. From this study cut-off points with a high positive and 




In order to use NT-proBNP as a biomarker of cardioembolic stroke is was necessary to 
determine its time course after ischemic stroke [3]. Existing information was contradictory. We 
measured NT-proBNP in the first 24, 48 and 72 hours after stroke onset. Although NT-proBNP 
serum levels started to decrease at 72 hours, the accuracy of NT-proBNP to diagnose 
cardioembolic stroke related to atrial fibrillation was similar in the three time points. This 
decrease of the serum levels after 72 hours may be related to the pattern of release of stored NT-
proBNP from the atria.  
To fully assess the potential utility of a biomarker, a proof of principle trials should be followed 
by a prospective validation study in which the diagnostic accuracy necessary for clinical utility 
is defined a priori. Individual studies tend to optimize the sensitivity and specificity of the cut-
off points. A new study was done to validate the established cut-off points and to see if their 
accuracy was reproduced. In order to do this an adequate sample size was calculated. To 
ascertain the feasibility of the test, the biomarker validation study was done in the clinical 
context in which the test would ultimately be used. In the validation study, the values of 
sensitivity and specificity of the previously established cut-off points were similar to the ones of 
the original study [4]. The next step was to test the cut-off points in patients with cryptogenic 
stroke and to see if they were useful to reclassify these ischemic strokes as having a 
cardioembolic etiology related to paroxysmal atrial fibrillation. Patients with cryptogenic stroke 
by definition cannot have evidence of significant systolic dysfunction, akinetic or hypokinetic 
ventricular segments or else they would have been classified as having a cardioembolic stroke 
etiology. After an extensive investigation including, patients with cryptogenic stroke were 
followed during one year after stroke onset and did serial Holter ECG monitorings to track atrial 
fibrillation [4]. There is no ideal method to detect paroxysmal atrial fibrillation. It is possible 
that episodes of paroxysmal atrial fibrillation may have not been detected. This may partially 
responsible for a slight decrease of the sensitivity and specificity of the cut-off points, 
nevertheless the accuracy of the NT-proBNP levels at the time of the stroke onset to diagnose 
atrial fibrillation was still good.  
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Although in the validation study, median levels of NT-proBNP in patients with paroxysmal 
atrial fibrillation were lower than median levels in patients with combined permanent, persistent 
and paroxysmal atrial fibrillation, the accuracy of NT-proBNP to diagnose paroxysmal atrial 
fibrillation was good (AUC-0.83). This report of different values of NT-proBNP according to 
atrial fibrillation was recently reported.   
To a biomarker to be useful it needs to have incremental benefit over existing diagnostic and 
clinical assessment. There are several predictors of paroxysmal atrial fibrillation that are used in 
clinical practice, including a dilated left atrial on echocardiography, premature atrial and 
ventricular beats of ECG and the stroke pattern on MRI.  However, they have a low accuracy. In 
our study patients with an initial cryptogenic stroke that were later reclassified as having atrial 
fibrillation or not did not differ regarding atrial dilatation. Biomarkers such NT-proBNP may be 
integrated with patient history, clinical assessment, and radiographic data to help to choose 
patients in whom an extended cardiac monitoring may helpful to unmask the occult paroxysmal 
atrial fibrillation. In patients with increased levels of NT-proBNP it may be reasonable to 
recommend longer monitoring with an implantable loop recorder, if the initial 30-day period 
fails to reveal atrial fibrillation. Thus, biomarkers could serve as an adjunct to clinical and 
imaging assessment. Also, the NT-proBNP serum measurements can be performed in minutes 
and is easier to the patient and less expensive than routine workups, such as transthoracic 
echocardiography or Holter monitoring or other cardiac imaging modalities such as 
transesophageal echocardiography or cardiac MRI. Also NT-proBNP serum measurements do 
not have the intra and interobserver variability of the previously mentioned exams.  
Currently, it is not possible to indicate that patients with NT-proBNP above a predefined cut-off 
level should begin anticoagulation. A recent study tried to determine in a retrospectively  
design if the effectiveness of warfarin and aspirin in preventing recurrent ischemic stroke or 
death over 2 years after the initial stroke  in noncardioembolic stroke patients differed according 
to previously determined NT-proBNP levels [5].  This study measured NT-proBNP in serum 
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collected at the baseline as part of the Antiphospholipid Antibodies and Stroke Study (APASS), 
a prospective cohort study within the Warfarin–Aspirin Recurrent Stroke Study (WARSS).  
Unfortunately, prolonged cardiac rhythm monitoring was not performed in WARSS and it is not 
known if patients with elevated NT-proBNP levels developed atrial fibrillation during the 2-
year follow-up. In this study, in those with NT-proBNP >750 pg/mL, the hazard ratio was 0.30 
(95% confidence interval: 0.12–0.84; p=0.021) significantly favoring warfarin over aspirin. It 
concluded that for secondary stroke prevention, elevated NT-proBNP concentrations could 
identify a subgroup of ischemic stroke patients without known atrial fibrillation, who could 
benefit more from anticoagulants than from antiplatelet agents.  
Ideally a randomized clinical trial of patients with cryptogenic stroke with serum levels of NT-
proBNP above 912 g/ml should be done in order to determine if these patients benefit from 
anticoagulation versus antiplatelets regarding stroke recurrence.  
There are some studies that evaluated the accuracy of BNP instead of NT-proBNP to diagnose 
cardioembolic stroke. We decided to use NT-proBNP instead of BNP in most of the studies 
because it has a higher half-life and is reported to be more stable upon freezing of the blood 
samples. There are no studies that have directly evaluated the accuracy of NT-proBNP versus 
BNP to diagnose cardioembolic stroke in patients with cryptogenic stroke. Further studies are 
necessary to compare head to head their diagnostic accuracy.  
A main strength of our study was that was done in the clinical context in which it should be 
applied in a ward during the regular etiological evaluation of stroke etiology. Nevertheless it is 
necessary to obtain an external validation of the cut-off points. It is necessary to evaluate which 
was the degree of optimism of the internal validation study. NT-proBNP measured within the 
first 72 hours after the onset of ischemic stroke may be useful to diagnose atrial fibrillation in 
patients with strokes initially classified as cryptogenic. NT-proBNP is a relatively inexpensive 
and widely performed blood test that may be useful as a biomarker of paroxysmal atrial 
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 NT-proBNP serum levels decrease significantly in the first 72 hours after ischemic 
stroke.   However, the diagnostic accuracy to diagnose a cardioembolic etiology is 
similar across the first 72 hours  
 The cut-off points of 265.5 pg / mL and 912.0 pg / mL of NT-proBNP had a sensitivity, 
specificity, positive predictive value and negative predictive value in the first study 
versus validation study of respectively 94.4% vs 100%, 72.9% vs 70.5%, 56.6% vs 
59.1%, 97.2% vs 100% versus 55.5% vs 81.8%, 97.9% vs 87.5, 90.9% vs 73.8%, 83.9 
vs 91.9% for the diagnosis of ischemic stroke of cardioembolic etiology associated to 
atrial fibrillation.  
 The Area Under the Curve of the Receiver Operating Curve of NT-proBNP for 
the diagnosis of paroxysmal atrial fibrillation  in patients with cryptogenic stroke 
was good - 0.83, 95% CI (0.73-0.92), the cut-off point of 265.5 pg/mL had a 
 sensitivity of 88.2% 95% CI (65.7-96.7%). The cut-off point of 912 pg/mL had a 
specificity of 88.9% 95% CI (78.8-94.5%).  
 In a population based study, patients with higher levels of BNP at the time of an 
undetermined stroke etiology onset had a higher probability of recurrence related to 
atrial fibrillation than patients with lower levels of BNP. 
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